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ROLE OF KCNMA1 IN THE PATHOGENESIS OF GEPD S YNDROME
WEI DU
ABSTRACT
The coexistence of generalized epilepsy and paroxysmal dyskinesia within the
same individual is an increasingly recognized neurological syndrome, with
both sporadic and familial cases reported. The basic pathophysiology
underlying GEPD is unknown, and no specific genes have been identified for it.
In order to identify genes associated with GEPD, a genome-wide linkage scan
was carried out in a Caucasian family affected by GEPD. A disease locus was
mapped on chromosome 10q22 and a mutation was identified in KCNMA1
encoding

the

pore-forming

α–subunit

of

the

large

conductance

calcium-activated potassium channel (BK channel). The mutant BK channel
showed a markedly greater macroscopic current and an increase in calcium
sensitivity. We propose that enhancement of BK channels in vivo leads to
increased excitability by inducing rapid repolarization of action potentials,
resulting in GEPD by allowing neurons to fire at a faster rate. These results
identify a gene that is mutated in GEPD and support the role of ion channels in
the pathogenesis of this syndrome.
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CHAPTER I
INTRODUCTION

1.1 Channelopathies in Epilepsy
Epilepsy is one of the most common chronic neurological disorders,
affecting about 50 million people worldwide (1). It is characterized by recurrent
unprovoked seizures, and increases risk of trauma and sudden death (2).
Epileptic seizures are transient occurrence of signs and/or symptoms due to
abnormal excessive or synchronous neuronal activity in the brain (3).
Epilepsies are classified into three groups by location or distribution of seizures
and by causes. Partial or focal epilepsies arise from a small portion of the brain
that drives the epileptic response. Generalized epilepsies, in contrast, arise
from epileptic circuits that involve the whole brain. The third group is epilepsies
of unknown localization (4).
Mutations in over seventy genes have been linked to different types of
epilepsies. Many of these identified genes encode ion channels, suggesting
ion channel defects as a genetic cause of epilepsies (Table I).
1

Multiple voltage-gated sodium channel mutations have been identified in
epileptic patients. Sodium channels are composed of α and β subunits. The α
subunits are transmembrane proteins with four homologous domains. They
contain voltage sensors and pore regions (5). The β subunits bind to the α
subunits and regulate cell surface expression, voltage dependence, and
kinetics of the α subunits (6).
A mutation in the sodium channel β1 subunit gene SCN1B was identified
in an Australian family with generalized epilepsy with febrile seizures plus
(GEFS+) (7). The mutation results in impaired modulation of sodium channel
function (8). In 2000, GEFS+ patients in two families were found to carry
mutations in SCN1A encoding the α1 subunit (9). Subsequently, eleven
additional SCN1A mutations were reported in GEFS+ families (10). SCN1A
mutations were also identified in patients affected by severe myoclonic
epilepsy of infancy (SMEI) (11).
The SCN1A mutations alter sodium channel functions in several
different ways. Three mutations (T875M, W1204R, and R1648H) lead to
impaired channel inactivation and an increased persistent current. In neurons,
this persistent current may reduce depolarization threshold of action
potentials, resulting in neuronal hyperexcitability (12). The interaction
between the α and β subunits was impaired by the D1866Y mutation. It was
shown that neurons expressing mutant channels fire an action potential at a
higher frequency (13). R1648H mutant channels displayed an increased rate
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Table I. Ion channels implicated in epilepsy
Channel
Sodium channel

Gene

Syndrome

SCN1A

Generalized epilepsy with febrile seizures
plus

SCN2A

Benign familial neonatal infantile seizures

SCN1B

Generalized epilepsy with febrile seizures
plus

Potassium

KCNQ1

channel

Calcium channel

ataxia

type

1

and

partial

epilepsy
KCNQ2

Benign familial neonatal convulsions

KCNQ3

Benign familial neonatal convulsions

KCNAB2

Severe seizures

CACNA1A
CACNB4

Chloride channel

Episodic

CLCN2

Generalized epilepsy
Generalized epilepsy and episodic ataxia
Idiopathic generalized epilepsy

3

of recovery from inactivation, another route to hyperexcitability (14).
Mutations in SCN2A are not common as SCN1A in epileptic patients.
Only a few mutations have been identified in patients with benign familial
neonatal infantile seizures (15, 16). The underlying molecular mechanisms
remain to be investigated.
The KCNQ family of voltage-activated potassium channels plays an
important role in repolarization of action potentials in cardiomyocytes,
neurons and vascular smooth muscle cells (VSMCs) (17). KCNQ2 encodes
the α subunit of a potassium channel composed of six transmembrane
domains and a pore region. A 5-bp insertion in the coding region of KCNQ2
was identified in an Australian family with benign familial neonatal convulsion
(BFNC) (18). The frameshift insertion results in a truncated protein with 300
less amino acids that was unable to produce currents when expressed in cells.
Loss-of-function of the mutant KCNQ2 channel leads to impaired
repolarization, which is likely to be the molecular mechanism for the
pathogenesis of BFNC. In addition, six other mutations in KCNQ2 were later
reported that are associated with BFNC (19).
Two other genes of this family, KCNQ1 and KCNQ3, have also been
linked to epilepsies. A Gly263Val missense mutation was identified in the pore
region of KCNQ3 channel in a Mexican-American family with BFNC (20). This
mutation was hypothesized to alter excitability of the cells through the same
pathway as KCNQ2. A Thr226Arg mutation was identified in the second
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transmembrane domain of the KCNQ1 channel in the patients affected by
both episodic ataxia type 1 and partial epilepsy (21). Electrophysiological
studies showed that expression of the mutant KCNQ1 channels in cells
significantly decreased the peak currents, which were only about 3% of those
of the wild-type channels. Mice lacking KCNQ1 channels displayed frequent
spontaneous

seizures

which

are

the

characteristic

of

epilepsies.

Electrophysiological studies indicated that action potentials are induced at a
lower threshold in nerve cells lacking KCNQ1 and the axonal conduction of
action potentials was also altered (22,23).
Loss of the regulatory β subunit KCNAB2 in eight patients resulted in
severe seizures (24). The KCNAB2 knockout mice displayed occasional
seizures which are similar to those observed in KCNQ1 knockout mice (25).
Loss of the β subunit might prolong membrane repolarization.
CACNA1A is a voltage-gated P/Q-type calcium channel expressed in the
brain. A C5733T mutation was identified in CACNA1A, and resulted in a
truncated protein without the C-terminal region of the channel in patients with
generalized epilepsy (26). Electrophysiological studies indicate that the
mutation impaired channel function in a dominant negative fashion.
CACNA1A knockout mice developed rapidly progressive neurological deficit
with specific characteristics of ataxia and dystonia (27). Further studies
demonstrated that calcium currents were completely eliminated in cerebellar
granule cells. Synaptic transmission was not affected but showed enhanced
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reliance on N-type and R-type calcium channels, indicating that CACNA1A is
also involved in synaptic transmission.
Two mutations have been identified in the β4 subunit gene of the
voltage-gated

calcium channel

CACNB4

in

families

with

idiopathic

generalized epilepsy and episodic ataxia. C104F is a missense mutation, and
R482X results in a truncated protein lacking 38 amino acids in the C-terminal
domain (28). Expression of the R482X mutant protein in Xenopus oocytes
showed slowed inactivation of the calcium channels. Considering that the
truncation site is located in the domain interacting with the pore-forming α
subunit, it is likely that the mutant β subunit alters channel functions by
impairing its association with the α subunit.
The ducky mouse is a model of absence epilepsy characterized by
spike-wave seizures and ataxia. Genetic analysis of the ducky mice identified
two mutations in the Cacna2d2 gene encoding the α2δ2 voltage-dependent
calcium channel subunit. Both mutations were predicted to cause loss of the
full length α2δ2 protein (29). Because normal α2δ2 subunit increases the
maximum conductance of the pore-forming α subunit in combination with the
β4 subunit, it is likely that loss of the α2δ2 subunit in ducky mice is
responsible for the reduced calcium channel currents in cerebellar Purkinje
cells of the ducky mice.
Three mutations have been identified in the chloride channel gene
CLCN2 in three unrelated families with idiopathic generalized epilepsy (IGE).

6

The mutations include a single-nucleotide frameshift insertion (M200fsX231),
a 11-bp deletion in intron 2 resulting in a splicing variant lacking exon 3
(Delexon3), and a missense mutation (G715E) (30). Normal CLCN2 channels
are activated during the hyperpolarization phase of the cell membrane by
both membrane potential and intracellular chloride. Expression of the
M200fsX231 and Delexon3 mutant channels did not produce detectable
currents, indicating loss-of-function for both mutations. G715E mutant
channels generated normal currents, but they were activated at less negative
potentials at a given chloride concentration.
Many non-ion channel genes also contribute to the pathogenesis of
epilepsy. Mice deficient of genes encoding synaptic vesicle-related proteins
synapsins

and

SV2

experienced

severe

seizures

(179,

180).

Gamma-Aminobutyric acid (GABA) is an inhibitory neurotransmitter in the
central nervous system. Multiple genes involved in GABA synthesis
contribute to epileptic phenotypes, including GAD65 (181), EAAT1 (182) and
TNAP (183). Mutations in genes encoding different GABA receptor subunits
have been associated with epilepsy (184-188). Some other neurotransmitter
receptors also play a role in epilepsy, including glutamate (189), acetylcholine
(190), and serotonin receptors (191, 192).

1.2 Paroxysmal Dyskinesia
Paroxysmal dyskinesias (PD) are a heterogeneous group of neurological
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disorders characterized by recurrent brief episodes of abnormal involuntary
movements (31). PD can be classified into three main groups.
Paroxysmal kinesigenic dyskinesia (PKD) occurs in early childhood and
its attack frequency often decreases as the patients grow up. PKD is induced
by sudden movements or change in velocity (going from walking to running).
PKD patients have frequent attacks everyday and respond dramatically to low
doses of carbamazepine (32). Paroxysmal nonkinesigenic dyskinesia (PNKD)
is characterized by spontaneous attacks induced by alcohol, caffeine, stress,
or fatigue. PNKD is not as frequent as PKD, but it can last up to six to eight
hours in some cases (33). Paroxysmal exercise-induced dyskinesia (PED)
usually occurs after ten to fifteen minutes of continuing exercise, which is
different from PKD that is caused by initiation of movement. PED often occurs
in the legs after prolonged walking or running (34).
Like epilepsies, ion channel genes have also been linked to paroxysmal
dyskinesias. Four different missense mutations were identified in KCNA1
encoding a voltage-gated potassium channel, in patients with movement
disorders (35). A brain-specific P/Q-type calcium channel α1-subunit gene
CACNL1A4 was linked to patients with hemiplegic migraine and episodic
ataxia type-2, which has some clinical features similar to PD. Several
missense and frameshift mutations in the functional domains, as well as
polymorphism sin the 3’-UTR, were identified in CACNL1A4 (36). Together
with ion channel mutations identified in epilepsies, these results strongly
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suggest that ion channel defects play an important role in pathogenesis of
neurological diseases.
Non-ion channel genes have also been associated with paroxysmal
dyskinesia. In 2004, mutations in the myofibrillogenesis regulator 1 gene MR1
were identified in fifty patients affected by paroxysmal non-kinesigenic
dyskinesia from eight families (193). Recently, mutations in SLC2A1,
encoding the glucose transporter type 1, were reported to cause paroxysmal
exercise-induced dyskinesia (194, 195).
Linkage analysis mapped another genetic locus for PNKD to
chromosome 2q31-36, but no specific gene has been identified (37, 38).
Interestingly, a cluster of sodium channel genes are located within this region.
PKD was linked to chromosome 16p12-q12 in several different families (39,
40). Although the specific gene causing PKD is unknown, this chromosomal
region contains ion channel genes, which may be good candidates for
mutational screening.

1.3 Coexistence of Epilepsy and Paroxysmal Dyskinesia
Epilepsy and paroxysmal dyskinesia are two distinct disorders with some
shared clinical features. PD patients lack both EEG abnormalities and
episodes of unresponsiveness during attacks that are found in epilepsy
patients (41). The coexistence of epilepsy and paroxysmal dyskinesia within
the same individual is an increasingly recognized neurological syndrome, with
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both sporadic and familial cases reported (42, 43).
ICCA is a syndrome characterized by infantile seizures and paroxysmal
kinesigenic dyskinesia (PKD). Linkage analysis mapped the ICCA disease
locus to a 10 cM pericentromeric region on chromosome 16 (44, 45). One
family with rolandic epilepsy and paroxysmal exercise-induced dyskinesia
(PED) was also linked to chromosome 16. The 6 cM disease locus is entirely
included in the ICCA locus, suggesting the same gene could be responsible
for both syndromes (46). Some other reports also linked coexistent epilepsy
and PKD to chromosome 16 in different populations (47, 48).
These

results

strongly

suggest

the

pericentromeric

region

of

chromosome 16 is tightly linked to epilepsy/PKD as well as epilepsy/PED, but
no specific gene in this region has been identified. Moreover, no genetic locus
has been mapped for coexistent epilepsy and paroxysmal nonkinesigenic
dyskinesia (PNKD). Ion channel defects may play an important role in the
pathogenesis of coexistent epilepsy and PD, as demonstrated in different
types of epilepsy and paroxysmal dyskinesia.

1.4 BK Channel
BK channels are activated by both membrane voltage and intracellular
calcium (49). They are expressed in many cell types including neurons (50),
hair cells (51), skeletal and smooth muscle cells (52, 53). BK channels play
important roles in a variety of physiological processes, such as neural
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transmission, muscle contraction and hearing. The pore-forming α subunit of
BK channel contains seven transmembrane domains (S0-S6) at the
N-terminus, a voltage-sensor (S1-S4), and a pore gate between S5 and S6.
The cytosolic C-terminal domain of BK channels has four hydrophobic
segments (S7-S10), the calcium bowl and the RCK (regulator of conductance
for K+) domain (54) (Figure 1). The calcium bowl is a high-affinity calcium
binding site (55), and the RCK domain contains binding sites for calcium and
magnesium (56, 57).
Four residues in the voltage-sensing domains (S1-S4) of the mouse BK
channel have been identified as the voltage-sensing residues: Asp153 and
Arg167 in S2, Asp186 in S3 and Arg213 in S4 (58). BK channels are less
sensitive to membrane voltage compared to voltage-gated potassium
channels such as Shaker, which has 12-13 effective gating charges (59). BK
channels can be activated by membrane voltage in the absence of calcium
(60). Like voltage-gated potassium and sodium channels, membrane voltage
causes the displacement of the charged residues in the voltage-sensing
domains, inducing channel opening (61).
BK channels can also be activated by binding of intracellular calcium to its
cytosolic domain, and the activation can be independent of membrane
voltage (62). There are at least two calcium binding sites in the cytosolic
domain of the pore-forming α subunits of the BK channel. One site is known
as the calcium bowl which contains a series of Asp residues, and the other
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site is located within the RCK domain (56). A model was proposed to explain
the coupling between calcium binding and channel opening. Binding of
calcium to the multiple binding sites changes the conformation of the RCK
domain. As a result of the conformational change, the gating ring expands to
increase in diameter resulting in channel opening (63).
Although both voltage and calcium can activate BK channels
independently, there are interactions between the two factors mediated by
channel opening. It was shown that opening of the channel gate by one factor
enhances the effect of the other (64).
Malfunction of BK channel leads to many diseases. Mice lacking the α
subunit of BK channel has abnormal conditioned eye-blink reflex and
abnormal locomotion and motor coordination (65). These mice also
developed high-frequency hearing loss at eight weeks of age (66). The β4
subunit of BK channel broadens action potentials by preventing the α subunit
from inducing the repolarization phase of the action potential. β4 knockout
mice displayed distinctive seizures emanating from the temporal cortex, and
the granule cells from these mice had a higher firing frequency (67). The
calcium sensitivity of BK channel was reduced in mice deficient for the β1
subunit, and the mice showed an increase in arterial tone and blood pressure
(68). A single nucleotide polymorphism C818T in the β1 subunit was found to
be associated with asthma in African American male asthmatics (69).
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Figure 1.

Structure of the BK channel. The BK channel contains seven

transmembrane domains (S0-S6), a pore gate between S5 and S6, four
hydrophobic segments (S7-S10), the calcium bowl and the RCK domain.
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In summary, these results suggest that BK channel α subunit, as well as
its auxiliary β subunits, play important roles in a variety of physiological
processes.

14

CHAPTER II
D434G MUTATION OF KCNMA1 IN GEPD FAMILY

2.1 Abstract
The coexistence of epilepsy and paroxysmal dyskinesia in the same
individual or family is an increasingly recognized phenomenon. The purpose of
this study was to identify the gene that is mutated in generalized epilepsy and
paroxysmal dyskinesia (GEPD) in an American family. Genomic DNA was
solated from blood of the family members. A genome-wide linkage scan with
382 microsatellite markers identified a disease locus on chromosome 10q22.
Fine mapping and haplotype analysis using eight additional markers defined
the disease-associated interval to a region of 8.4 cM flanked by markers
D10S1694 and D10S201. Candidate genes in this region was screened for
mutations by sequencing and a heterozygous point mutation A1301G was
identified in exon 10 of KCNMA1, encoding the pore-forming α subunit of BK
channel. The A1301G mutation results in the substitution of a negatively
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solated from blood of the family members. A genome-wide linkage scan with
382 microsatellite markers identified a disease locus on chromosome 10q22.
Fine mapping and haplotype analysis using eight additional markers defined
the disease-associated interval to a region of 8.4 cM flanked by markers
D10S1694 and D10S201. Candidate genes in this region was screened for
mutations by sequencing and a heterozygous point mutation A1301G was
identified in exon 10 of KCNMA1, encoding the pore-forming α subunit of BK
channel. The A1301G mutation results in the substitution of a negatively
charged aspartic acid residue for a neutral glycine residue (D434G) in the
regulator of conductance for K+ (RCK) domain. A1301G was present in 13
affected individuals and absent in 5 unaffected individuals in the family.
Furthermore, the mutation was not detected in 500 unrelated healthy controls.
Together, these results suggest that A1301G in KCNMA1 is responsible for
GEPD in this family.

2.2 Introduction
Epilepsy is one of the most common chronic neurological disorders,
affecting about 50 million people worldwide (1). It is characterized by
recurrent unprovoked seizures, and increases risks of trauma and sudden
death (2). Mutations in over seventy genes have been linked to different types
of epilepsies. Many of these identified genes encode ion channels,
suggesting ion channel defects as a genetic cause of epilepsies (Table I).
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Paroxysmal

dyskinesias

(PD)

are

a

heterogeneous

group

of

neurological disorders characterized by recurrent brief episodes of abnormal
involuntary movements (31). Epilepsy and paroxysmal dyskinesia are two
distinct disorders with some shared clinical features. PD patients lack both
electroencephalography

(EEG)

abnormalities

and

episodes

of

unresponsiveness during attacks that are found in epilepsy patients (41). Like
epilepsy, ion channel genes have also been linked to paroxysmal dyskinesias
(35, 36).
The coexistence of epilepsy and paroxysmal dyskinesia within the same
individual is an increasingly recognized neurological syndrome, with both
sporadic and familial cases reported (42, 43). Previous results suggest the
pericentromeric region on chromosome 16 is tightly linked to coexistent
epilepsy and paroxysmal dyskinesia (45-48), but no specific gene in this
region has been identified.
Here we report that a region of 8.4 cM flanked by markers D10S1694 and
D10S201 on chromosome 10q22 is associated with coexistent generalized
epilepsy and paroxysmal dyskinesia in an American family, and show that a
point mutation in the BK channel α subunit gene KCNMA1 co-segregates with
affected individuals in the family. These findings identify a new genetic locus
and a candidate gene for GEPD.
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2.3 Materials and Methods
This study was approved by the Cleveland Clinic Institutional Review
Board on Human Subjects. Informed consent was obtained from all
participants or their guardians. The patients and family members were
identified and clinically characterized at the Department of Neurology of the
Cleveland Clinic Foundation. The family under study is of mixed European
descent, and was referred to this study from the adult epilepsy clinic due to
the diagnosis of epilepsy in multiple family members. A detailed pedigree was
constructed. Clinical information was obtained through semistructured
interviews in person and over the phone, conducted by a neurologist with
specialty training in epilepsy and clinical neurophysiology. Seizure histories
were corroborated by questioning eyewitnesses where possible. Records of
interictal EEG and video-EEG were obtained when applicable. Epilepsy was
defined as two or more unprovoked seizures. Seizure types were classified
according to the International Classification of Epileptic Seizures. Epilepsy
syndromes were classified according to the International Classification of
Epilepsies and Epileptic Syndromes.
The proband (IV-8) was interviewed at 21 years of age. She had normal
birth and early development. Routine neurological exam was normal. At two
years of age she developed episodes of involuntary mouth movement and
hand stiffness, lasting 10 seconds to two minutes, with preserved
consciousness; these occurred weekly, were more common with fatigue,
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were not triggered by sudden movement, and were diagnosed as PD. At
approximately the same age she developed separate episodes of loss of
awareness, with vacant staring and unresponsiveness, characteristic of
typical absence seizures. There was no aura, and these absence seizures
occurred daily in early childhood, progressively decreasing in frequency to
monthly seizures in adolescence, on medication. Routine EEG showed
generalized spike-wave-complexes.
Her paternal first cousin (IV-1) had episodes of vacant staring and
episodes of PD without loss of awareness. She was evaluated with inpatient
continuous video-EEG. Her interictal EEG showed generalized spike-wave
complexes. Episodes of vacant staring and eyelid fluttering were associated
with bursts of generalized spike-wave complexes, confirming their epileptic
nature. Episodes of PD were not associated with any EEG change,
confirming their non-epileptic nature. At five years of age she developed
generalized tonic-clonic seizures.
Epileptic seizures, in those other family members affected with epilepsy,
were typically absence seizures, with generalized tonic-clonic seizures in two
other individuals (IV-1, IV-2). The age of onset of absence seizures in the
family is earlier than usual for typical absence seizures, but such an early age
of onset has been described in a series of patients with coexistent absence
epilepsy and paroxysmal dyskinesia. The seizure types exhibited by this
family did not have any resemblance to benign familial neonatal seizures or
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benign infantile convulsions. There was no clear evidence for myoclonic
seizures in any of the affected individuals.
The proband’s seizures were responsive to valproate and lamotrigine.
The seizure frequency in the proband has varied from daily (when she was
younger and not taking medications regularly) to monthly (her seizure
frequency in current years on valproate and/or lamotrigine). Individuals IV-1
and IV-2 had seizures and PD partially responsive to clonazepam.
PD can be broadly classified into two main subtypes: paroxysmal
kinesigenic dyskinesia (PKD) if the attacks are induced by sudden movement
and paroxysmal non-kinesigenic dyskinesia (PNKD) if they are not. PD, in
those affected, were often described as involuntary dystonic or choreiform
movements of the mouth, tongue, and extremities, non-kinesigenic but
induced by alcohol, fatigue, and stress, most consistent with PNKD. PNKD in
this family had onset in childhood and showed a gradual decrease in
frequency with age, but persisted into the fourth decade in some individuals.
The human subjects had no complaints of hearing loss or other neurological
symptoms and had no evidence for hearing loss on routine neurological
exams.
Human genomic DNA was prepared from whole blood with the DNA
Isolation Kit for Mammalian Blood (Roche Diagnostic Co). Genome-wide
genotyping was carried out using 382 polymorphic, fluorescently labeled
microsatellite markers on chromosomes 1-22 (ABI PRISM Linkage Mapping
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Set-MD10). Additional markers were identified at the Genethon database, and
used for fine mapping and haplotype analysis. Markers were genotyped using
an ABI 3100 Genetic Analyzer (Applied Biosystems, Foster City, CA).
Allele-calling was carried out by GeneScan and GeneMapper 2 software
programs (Applied Biosystems). Linkage analysis and two-point LOD score
calculation were performed using the Linkage Package 5.2 assuming
autosomal dominant inheritance, penetrance of 99%, a phenocopy rate of 0%,
gene frequency of 1/10,000, and allele frequency of 1/n where n equals the
number of alleles observed.
Mutational analysis was carried out using direct DNA sequence analysis.
The genomic structure of the KCNMA1 gene was determined by comparing
the 3,537 bp cDNA sequence (GenBank accession number NM_002247) to its
genomic sequence, and was found to contain 27 exons. Polymerase chain
reaction (PCR) primers were then designed based on intronic sequences to
amplify all 27 coding exons (Table II). PCR products were purified from agrose
gels using the QIAquick PCR Purification Kit (QIAGEN, Valencia, CA) and
sequenced with both forward and reverse primers by an ABI3100 Genetic
Analyzer (Applied Biosystems).
Restriction fragment length polymorphism (RFLP) analysis was used to
confirm the D434G mutation and to test the presence/absence of the mutation
in other family members and 400 normal controls. The D434G mutation
creates a Tsp45I restriction site. The 201bp PCR fragment containing exon 10
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Table II.

PCR primers for amplification of KCNMA1 exons

Exon(s)
Forward Primer (5’ to 3’)
1
AGTAGCAGCAATATGGCTGTT
G
2
GGTTCTTTATGGGTAGAGCAT
G
3
AAACATCCTGAGGTCCAACTC
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21

AT
60°
C
58°
C
58°
C
GATGATACTACCTGTCATTTAC
58°
C
C
TGCCAGCACCATGCTTCTCATG ATTCTGTCCTTCAGCCATGACT 58°
C
C
AAATCAAATGGCAGACTGTGA CAAGCACACCTGATATTTGCA 58°
AC
AC
C
TGCTGTTACCCTGTAAGGCAG
AGAGGGTCTTGTTGCAGGCAA 58°
G
C
GCATGTATACACTTCAATAGC
GCTTCTAGTGCAGAATACAGT 58°
ATG
C
C
TATACCTTTGCAGGCCTAATCC GAGAGGATTCTACCGCAGCAG 58°
C
TGCAGGGTCCTGTCCGTGGT
ACCTCCACTCTTACAGACATTC 58°
C
CTGTGGAAATTAGAGAGGAAG TGGCCAACCTAGGAGGTGTG
58°
G
C
GAGACTACACTCGAGCATGGC GATAGTCCTCTGCAGAAGATC 58°
C
C
CTGCCTCCTACCTCAGTCCC
AGGAAGAAGAGGCTGGACCTG 58°
C
CCCAGAAGAAATGTTAAACAA TAAGCTGTGCTCTCTACTCAAC 53°
TTG
C
AAGAGTGTAACTCAGGTTTCC TCCAACTGTACCCAGCAGAGG 58°
C
C
CTCTGGTCATTCAGAAGAACT
TCAGAACGCACTCTCACCATC
58°
G
C
ACAACAGTATGGTGTAGCCTT CCGTGGGTCAAGGTGTCTAC
58°
C
C
CGTGGAGGAAATGTGGTACTC CATACTCAAGAAAACTCTCGA 53°
TG
C
GCCTTGAGTGTGTGTCCTTTG
CTTTAAGAAGCCATCTAACGA 58°
TC
C
CACATCCTCTGAGATGTAATTC CAGTATTATCCCACTGTCCAAC 58°
C
TAGCACATAGTAAGCTCTCAG AAGCTACAACTATTATATCCAT 58°
22

Reverse Primer (5’ to 3’)
AGAAGCGGTGGGGCTGGCGCA
G
CTCATAAGCAAAGCCACCTTG
G
ATCAATGTAAAGGCTCATGAT
TG
GACTGCGAGAGCAGAGGCTG

22
23

C
TCCCTCTCCTCTCACTTTTGC

24

GTTGTATGTATATAGTGTACTC
TG
CCTGGTCTCCCTCTGGCTTC

25

TTGGATGTCGGCTGTCATGAC

26

CCCTGCTGTCCCTTGATTTTC

27

GCTTTTGGTTCAGAGAGAGTT
G

CC
TACTGAGTGAAGGATATCCCT
C
AAACCAACCTCCTCATATCCTG

C
58°
C
58°
C
TGCTCTATTGGCACATCCTCC
58°
C
ATCTGATACCACGTTCTTCAGG 59°
C
CCTTTACAGTAGGGGACAGG
59°
C
GTTGGAAACACCAACTGGGG
58°
C

restriction enzyme Tsp45I. The digested product was separated by 2%
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agarose gels and analyzed.

2.4 Results
We studied a large family of five generations and thirty-one members with
coexistent generalized epilepsy and paroxysmal dyskinesia (GEPD). The
pedigree is shown in Figure 2. As paroxysmal dyskinesia in those affected
family members were involuntary movements of the mouth, tongue and
hands induced by alcohol, fatigue and stress, but not sudden movement, it is
classified as paroxysmal nonkinesigenic dyskinesia (PNKD). Sixteen affected
individuals developed epileptic seizures (n=4), PNKD (n=7) or both (n=5)
(Figure 2).
The detailed clinical features of 13 affected individuals, who participated
in subsequent genetic studies, are summarized in Table III. An example of
interictal EEG showing generalized spike-wave complex is shown in Figure 3.
Pedigree analysis suggested that the disease is inherited in an autosomal
dominant pattern in the family, because it is present in every generation and
in both males and females. In order to map generic locus linked to the
disease, we carried out a genome-wide linkage analysis with 382
fluorescently labeled microsatellite markers. The markers cover human
chromosome 1-22 at an average interval of 10 centimorgan (cM). One
centimorgan is equal to 1% chance that a marker at one locus on a
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Figure 2.

Genetic linkage of GEPD to chromosome 10q22 in family

QW1378. Pedigree structure and genotypic analysis of the family affected
with epilepsy (blue symbols), paroxysmal dyskinesia (PD; black symbols) or
both (green symbols). Squares represent males; circles, females. Filled
symbols denote affected individuals; open symbols, unaffected individuals.
Symbols with slashes through them denote deceased individuals. The
haplotype that cosegregated with the disease is indicated by a black vertical
bar.
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Table III.
ID

Clinical features of 13 affected individuals in family QW1378
Age at onset of Seizure Type

EEG

E

Age at onset of

Diagnosis

PD

II-02

--

--

--

13-15 years

PD

II-03

6 years

possible

normal, as

6 years

PD,

absence

adult

possible

--

N/A

E

III-02

8-9 years

possible E

absence
III-04

--

--

--

4-5 years

PD

III-05

--

--

normal, as

7 years

PD

adult
III-07

--

--

--

4-5 years

PD

III-09

--

--

--

3-4 years

PD

IV-01

<6 months

absence, rare

SWC gen

<6 months

E + PD

SWC gen

<6 months

E + PD

GTC
IV-02

3 years

absence, rare
GTC

IV-03

--

--

normal

4-5 years

PD

IV-04

--

--

normal

4-5 years

PD

IV-06

5-6 years

possible

normal

5-6 years

PD,

absence
IV-08

2 years

possible E

absence

SWC gen

26

2 years

E + PD

Affected family members were diagnosed with either paroxysmal dyskinesia
(PD), epilepsy (E), or both. SWC gen, generalized spike wave complexes
typical of idiopathic generalized epilepsy; GTC, generalized tonic-clonic
seizures.
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Figure 3.

Representative interictal EEG of an affected member of family

QW1378. EEG was recorded for individual IV-1 at 5 years of age. Ten-second
EEG tracing showing interictal generalized spike-wave complexes (3-3.5 Hz)
in individual IV-1 with both generalized epilepsy and paroxysmal dyskinesia.
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chromosome will be separated from a marker at another locus on the same
chromosome during meiosis. In genetics, cM is often used to imply distance
along a chromosome, and one cM is about one million base pairs in humans.
Markers D10S580 and D10S1730 on chromosome 10q22 showed
significant linkage to GEPD. Allele 4 of D10S580 and allele 5 of D10S1730
are present in all affected individuals but absent in all normal individuals in the
family. The Lod score is 3.68 for marker D10S580 and 3.73 for marker
D10S580. Lod score calculation is a statistical test often used to determine
linkage between two markers or a marker and a trait. By convention, a Lod
score greater than 3.0 is considered as evidence for linkage. A Lod score of
3.0 means the likelihood that the two markers (or a marker and a trait) are not
linked is less than 0.1%. Therefore, markers D10S580 (Lod score=3.68) and
D10S1730 (Lod score=3.73) are strongly linked to GEPD. No other markers
in the genome showed a Lod score of greater than 2.0, suggesting the
chromosomal 10q22 region was the only region linked to GEPD.
In order to define the centromeric and telomeric boundaries for the
disease-associated interval on chromosome 10q22, we carried out fining
mapping and haplotype analysis using eight additional markers near
D10S580 and D10S1730. Individual III-4 showed a recombination between
markers D10S1694 and D10S580, defining D10S1694 as the centromeric
boundary for the disease-associated interval (Figure 2). Individual IV-4 had a
recombination between D10S201 and D10S1730, which placed D10S201 as
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the telomeric boundary for the disease interval (Figure 2). Therefore, the
GEPD-associated interval in the family was mapped to a region of 8.4 cM
flanked by markers D10S1694 and D10S201 on chromosome 10q22 (Figure
4).
We

searched

the

Celera

database

for

genes

located

in

the

GEPD-associated locus on chromosome 10q22. We found forty genes,
including thirty-three known genes and seven hypothetical genes. Owing to
the importance of ion channels in epilepsy and paroxysmal dyskinesia
(discussed in Chapter I), we hypothesized that mutations in genes encoding
ion channels might cause GEPD. Out of the thirty-three known genes, two of
them encode ion channels. VDAC2 encodes voltage-dependent anion
channel 2, and KCNMA1 encodes the pore-forming α subunit of the BK
channel.
We carried out mutational screening of all the axons of VDAC2 and
KCNMA1 by direct DNA sequence analysis. We did not find any mutation in
the exons of VDAC2. We identified a heterozygous A to G transition in exon
10 of KCNMA1 in an individual (IV-8) of the family (Figure 5a). The A to G
transition results in the substitution of a negatively charged aspartic acid
residue for a neutral glycine residue (D434G) in the regulator of conductance
for K+ (RCK) domain (Figure 5b). It has been reported that the RCK domain
contains binding sites for calcium and magnesium (56, 57), thus it is likely that
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Figure 4.

Location of GEPD-associated locus on chromosome 10q22.

Ideogram of chromosome 10 showing Geimsa binding patterns. The
GEPD-associated locus is 8.4cM flanked by markers D10S1694 and
D10S201. The gene KCNMA1 is located between markers D10S580 and
D10S1730.
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Figure 5.

KCNMA1 mutation A1301G is present in individual IV-8 of family

QW1378. a) DNA sequence analysis of exon 10 of KCNMA1 from an
unaffected individual (III-10) and an affected individual (IV-8) identified an A to
G transition (reverse sequence) at codon 434 of individual IV-8, which results
in the replacement of a negatively charged aspartic acid residue with a
neutral glycine residue (D434G). b) Structure of the BK channel α subunit with
D434G mutation indicated. c) Asp434 of KCNMA1 is evolutionally conserved
among different species.
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the D434G mutation might alter the affinity of the RCK domain to calcium or
magnesium. Asp434 is located in a cluster of amino acids that are
evolutionally conserved among different species (Figure 5c), suggesting the
importance of this amino acid residue.
Next, we did mutational analysis of other family members whose blood
samples were available. The A1301G mutation was present in all thirteen
affected individuals that were genotyped and absent in five unaffected
individuals in the family. The result was confirmed by restriction fragment
length polymorphism (RFLP) analysis as the mutation creates a Tsp45I
restriction site (Figure 6). Furthermore, the mutation was not detected in five
hundred unrelated healthy controls. Taken together, these results suggest
that the A1301G mutation of KCNMA1 is responsible for GEPD in this large
family.
We studied another family (Figure 7) by mutational analysis. We
screened KCNMA1 mutations in two family members (IV-2 and IV-3), but no
mutations were found. We also carried out mutational analysis of KCNMA1 in
102 sporadic patients with epilepsy and/or paroxysmal and no KCNMA1
mutations were identified. There results suggest that BK channelopathy might
not be a common cause for epilepsy and/or paroxysmal dyskinesia.
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Figure 6.

KCNMA1 mutation A1301G cosegregates with GEPD patients in

family QW1378. The A1301G mutation creates a Tsp45I restriction site. The
201 bp PCR fragment containing the mutation site was digested with Tsp45I
and separated on agarose gel. Pedigree showing clinical status is shown on
the top. The results of RFLP analysis are shown below each individual. Wild
type allele, 201 bp, mutant allele, 83 bp and 118 bp.
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Figure 7.

Pedigree of another family with coexistent epilepsy and

paroxysmal dyskinesia. Different phenotypes are indicated by different colors,
psychosis (yellow), migraine (orange), epilepsy (blue) and paroxysmal
dyskinesia (black). Three family members (IV-2, IV-3 and V-2) have
coexistent epilepsy and paroxysmal dyskinesia.
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2.5 Discussion
Previous studies on coexistent epilepsy and paroxysmal dyskinesia
suggest that the pericentromeric region on chromosome 16 is tightly linked to
this syndrome. The genetic locus for ICCA syndrome characterized by
infantile seizures and paroxysmal kinesigenic dyskinesia (PKD) was mapped
to a 10 cM region on chromosome 16 (44, 45). Other reports also confirmed
the linkage between the pericentromeric region on chromosome 16 and
coexistent epilepsy and PKD (46-48). However, no specific gene that is
mutated in the patients has been identified in this region. Thus, the KCNMA1
gene identified here is the first gene reported for coexistent epilepsy and PD.
The patients in family QW1378 were diagnosed as coexistent epilepsy
and paroxysmal nonkinesigenic dyskinesia (PNKD). The linkage between the
pericentromeric region on chromosome 16 to the GEPD patients in family
QW1378 was excluded by our genotyping and linkage analysis. None of the
microsatellite markers on chromosome 16 showed a Lod score of greater
than 2.0. These results suggest that although PKD and PNKD have similar
clinical features, the molecular mechanism underlying the pathogenesis of
the two syndromes might be different. The 10q22 region is the first genetic
locus identified for coexistent epilepsy and PNKD. Different mutations in
KCNA1 are associated with different neurological phenotypes, including
partial seizures (70), but KCNA1 mutations have not been reported as a
cause of coexistent seizures and paroxysmal dyskinesia in a single individual.
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Mutations in potassium channel genes KCNQ2 and KCNQ3 are associated
with benign familial neonatal seizures (71), which are different from the
absence seizures and generalized tonic-clonic seizures observed in family
QW1378.
The BK channel is different from other voltage-activated potassium
channels in that it can be activated by both membrane voltage and
intracellular calcium. The BK channel is formed by four transmembrane α
subunits. The β subunits bind to the α subunits and regulate their activities.
The BK channel is a good candidate for mutational screening in GEPD
patients because it plays important roles in neural transmission and muscle
contraction.
The RCK domain is an intracellular motif that contains binding sites for
both calcium and magnesium. The D434G mutation is located in the RCK
domain, suggesting that it might be important for calcium binding. The human
D434 residue corresponds to D369 of mouse KCNMA1. D369 is the second
aspartic acid residue of the interloop connecting motifs αA and βB of the RCK
domain. Amino acids DRDD were mutated to KSGE in mouse KCNMA1 and
subjected to electrophysiological studies, and the results indicated that the
four amino acids play an important role in calcium dependent activation of BK
channel (67). Mutation of DRDD to KSGE has no effect on magnesium
sensitivity. Therefore, D434G mutation might cause GEPD by altering calcium
sensitivity of the RCK domain.
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In conclusion, results from the current study demonstrate that
chromosome 10q22 is tightly linked to GEPD in family QW1378 and that the
A1301G mutation of KCNMA1 cosegregates with the affected individuals in
the family. Further functional characterization of the mutant BK channel may
shed light on the molecular mechanism underlying the pathogenesis of
GEPD.
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CHAPTER III
D434G INCREASES CALCIUM SENSITIVITY OF BK CHANNEL

3.1 Abstract
Cosegregation of the D434G mutation of KCNMA1 with GEPD in family
QW1378 suggests that a BK channel defect is the cause for this syndrome.
The purpose of this study was to investigate the effect of the D434G mutation
on BK channel function. Electrophysiological studies were performed in both
Xenopus laevis oocytes and Chinese hamster ovary (CHO) cells using
wild-type and mutant BK channels. The mutant channel had a markedly
greater macroscopic current in Xenopus laevis oocytes. At a calcium
concentration of 0.1μM and 2μM, the mutant channel was activated at lower
membrane voltage. Single-channel recordings in CHO cells showed that at a
given membrane voltage and calcium concentration, the mutant channel spent
more time in the open state. Consistent with the results from Xenopus laevis
oocytes, mutant BK channel was activated at lower voltage at a given calcium
concentration. Together, these results suggest that the primary effect of the
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D434G mutation was to increase calcium sensitivity, rather than to affect the
voltage sensor, which is consistent with the role of the RCK domain as a high
affinity site for calcium. It is likely that increased calcium sensitivity of the
mutant BK channel leads to enhanced excitability by inducing rapid
repolarization of the action potential, resulting in GEPD by allowing neurons
to fire at a faster rate.

3.2 Introduction
BK channels play important roles in a variety of physiological processes,
including neural transmission, muscle contraction and hearing. Mice lacking
the α subunit of BK channel developed abnormal conditioned eye-blink reflex,
impaired locomotion and motor coordination, and high-frequency hearing loss
(65, 66). Mice deficient of the β4 subunit showed distinctive seizures (67),
while the β1 subunit deficient mice showed increased arterial tone and blood
pressure (68). A polymorphism in the β1 subunit was associated with asthma
in African American male asthmatics (69). Despite the important physiological
roles of BK channels, no mutation in the pore-forming α subunit has been
associated with human disorders such as epilepsy.
The BK channel is activated by both membrane voltage and intracellular
calcium. Beside the calcium bowl, the RCK domain contains high affinity sites
for calcium binding, which has been demonstrated for the mouse homolog of
human KCNMA1. The D434G mutation identified in family QW1378 is located
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in the RCK domain of KCNMA1, suggesting it might affect the calcium
sensitivity of the channel, resulting in GEPD.
Here we report the results of electrophysiological studies in both Xenopus
laevis oocytes and mammalian CHO cells using wild-type and mutant BK
channels. Greater macroscopic currents were detected in Xenopus laevis
oocytes expressing the mutant channel. At a given calcium concentration, the
mutant channel was activated at lower membrane voltage. In CHO cells, the
mutant channel spent more time in the open state compared with the
wild-type channel. At a given membrane voltage, the mutant channel was
activated at lower calcium concentrations. Together, these results suggest
that the D434G mutant BK channel has increased sensitivity to calcium.
This study establishes that the D434G mutation of the BK channel causes
GEPD in family QW1378 by increasing sensitivity to calcium (a
gain-of-function mechanism). It also suggests that BK channel inhibitor might
be used as a potential therapy for coexistent epilepsy and paroxysmal
dyskinesia.

3.3 Materials and Methods
The human KCNMA1 cDNA was cloned into plasmid pcDNA3, resulting in
an expression construct for the BK channel (kind gifts from Drs. Irwin B.
Levitan and Yi Zhou at University of Pennsylvania School of Medicine and
from Drs. Larry Salkoff and Alice Butler from Washington University Medical
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School). The D434G mutation was introduced into the KCNMA1-pcDNA3
construct by PCR-based site-directed mutagenesis, and confirmed by
sequencing analysis of the full KCNMA1 insert.
To create the expression constructs for Xenopus oocyte expression, we
subcloned the full-length wild type and mutant KCNMA1 cDNA into the pSP64
Poly(A) vector (KCNMA1-pSP64) using restriction enzymes Hind III and XbaI.
To create the expression constructs for CHO cell expression, we subcloned
KCNMA1 cDNA into a GFP vector pIRES2-EGFP (Clontech) with the
restriction enzymes NheI and XhoI.
KCNMA1-pSP64 construct was digested with EcoR I, and cRNA was
prepared using the In Vitro Transcription kit with SP6 polymerase. 5 ng of
cRNA was injected into each Xenopus laevis oocyte 2-6 days before
recording. Macroscopic currents were recorded from inside-out patches
formed with borosilicate pipettes of 0.9~1.8 megohm resistance. Data were
acquired using an Axopatch 200-B patch clamp amplifier (Axon Instruments)
and Pulse acquisition software (HEKA Electronik). Records were digitized at
20-µs intervals and low pass filtered at 10 KHz with the Axopatch’s 4 pole
Bessel filter. Typically, during G-V measurements the series resistance at
maximum current amplitude will cause a voltage error of ≤ 5 mV. The error will
be smaller at voltages where the activation of channels is not saturated. The
shape of the G-V relation and its voltage range affected by this error are
smaller than the standard deviation. The pipette solution contained (mM): 140
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K-Methanesulfonic Acid, 20 Hepes, 2 KCl, 2 MgCl2, pH 7.20. The basal
internal solution contained (mM): 140 K-Methanesulfonic Acid, 20 Hepes, 2
KCl, 1 EGTA, pH 7.20. CaCl2 was added to internal solutions to give the
appropriate free [Ca2+]i. All recordings were obtained at room temperature
(22-24oC).
For single channel recordings from Chinese hamster ovary (CHO) cells,
KCNMA1 cDNA (wild type and mutant) were subcloned into a pIRES2-EGFP
vector (Clontech) with the restriction enzymes NheI and XhoI. CHO cells were
plated onto coverslips in 12 well Falcon plates, and transfected (0.8 µg
DNA/well) using lipofectamine (4 µl/well; Life Technologies) 6-12 hours before
recording. Coverslips were placed in a recording chamber on an inverted light
microscope (Axiovert 100, Zeiss) and superfused with Ringer solution at 2
ml/min. Transfected cells were selected by visualizing GFP fluorescence.
Patch-clamp recordings were made with borosilicate glass electrodes
fabricated using a P-97 microelectrode puller (Sutter Instr.). Microelectrodes
(20-100 MΩ) were filled with a solution containing (in mM): 144 KCl, 16 NaCl,
2 MgCl2, 2 TES, 11 glucose, 0.065 CaCl2, and 0.08 EGTA. After obtaining a
patch, the electrode tip was moved into a separate minichamber, and the
inside face of the patch was exposed to the same solution (flow rate 1 ml/min)
in which the amount of CaCl2 was varied to give a free calcium concentration
of 1, 2, 5, 10, 20, 50, or 100µM (calculated using Webmaxc;
www.standford.edu/~cpatton/maxc.html).
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Recordings

of

single

channel

currents were made in the inside-out configuration from patches with 1-6
channels. These recordings were performed at room temperature in voltage
clamp from a holding potential of –60 mV to test potentials from –100 to
+100mV (steps of 20 mV for 3 seconds each). Currents were low pass filtered
at 2 kHz, and digitized at a rate of 10 kHz using an Axopatch 1D amplifier,
Digidata 1322a A/D converter and PClamp software (Axon Instruments). The
number of channels in each patch was determined using all points histograms
from recordings performed at each level of calcium and voltage. If these
histograms did not clearly reveal the number of channels present, the data
from that patch were rejected. The open channel probability was analyzed
using Clampfit software (Axon Instruments) and the data were fit to the
Boltzmann and Hill equations using Origin Software (OriginLab Corp).

3.4 Results
Wild-type and D434G mutant channels were expressed in Xenopus laevis
oocytes and current-voltage relations were recorded. At a calcium
concentration of 2 μM, there was more current induced at the same
membrane potential in oocytes expressing D434G mutant channels than in
oocytes expressing the wild-type channels (Figure 8a). The voltage
dependence of steady-state activation (G-V relation) was shifted to more
negative potentials by the D434G mutation, with little change in the slope of
the curve. At a calcium concentration of 0.1μM, the G-V relation was shifted
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~26 mV toward more negative potential in oocytes expressing the mutant
channels. At a calcium concentration of 2 μM, the G-V relation was shifted
~57 mV toward more negative potential by the D434G mutation (Figure 8b).
These results indicate that the mutant BK channel has an increased voltage
and calcium-dependent activation. Corresponding to the shifts in voltage
dependence of activation, the mutant channels were activated faster than the
wild-type channels in response to a depolarizing voltage. At a calcium
concentration of 2 μM and a test potential of 100 mV, the mutant channels
were activated in about 4 ms following the depolarizing voltage pulse, while
the wild-type channels were activated in about 7 ms.
These results suggest that during an action potential in neurons, in
response to depolarization and calcium entry through voltage-dependent
calcium channels, more mutant BK channels open, causing a rapid
repolarization of the action potential (72). To better define the mechanism of
the increase in macroscopic currents, we made single-channel recordings
from BK channels expressed in CHO cells. Both the wild-type channel and
the D434G mutant channel were activated by an increase in membrane
voltage or in intracellular calcium concentration, but at a given voltage and
calcium concentration, the mutant channel was more likely to be in the open
state (Figure 9a). At a calcium concentration of 10 µM, the mutant channel
was activated at a membrane voltage that is about 50 mV lower than the
voltage needed for activation of the wild-type channel. Similar results were
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Figure 8.

Electrophysiological characterization of wild-type and D434G

mutant channels in Xenopus laevis oocytes. a) Selected current traces of WT
(left) and D434G mutant (right) channels at 2 µM [Ca2+]i. Test potential were
-10 to +140 mV with 50-mV increments. The holding and repolarizing
potentials were -80 and -50 mV. b) Mean G-V relations of WT and D434G
mutant channels at 0.1 and 2 µM [Ca2+]i. All G-V relations are fitted with the
Boltzmann relation (solid lines) with V1/2 and slope factor at 2 µM [Ca2+]i: 116
± 5 mV, 20.6 ± 4.4 for WT and 58.9 ± 4.8 mV, 17.6 ± 4.3 for D434G; and at 0.1
µM [Ca2+]i: 184 ± 8 mV, 20.5 ± 6.3 for WT and

157 ± 5 mV, 20.3 ± 4.2 for

D434G. c) Plots of activation time constants of WT and D434G mutant
channels as a function of test potential at 0.1 and 2 µM [Ca2+]i. The curves are
fitted with an exponential function (solid lines).
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obtained at calcium concentration of 2 µM and 50 µM (Figure 9b). These
results are consistent with the results from oocytes recordings (Figure 8b).
At membrane voltage of 60 mV and 80 mV, the mutant channel was
activated at lower calcium concentrations (Figure 9d). These results suggest
the D434G mutation increased calcium sensitivity of the BK channel, which is
consistent with the role of the RCK domain as a high affinity site for calcium
binding. The relationship between membrane voltage, intracellular calcium
concentration and channel activation is shown in Figure 9c. At a given
calcium concentration, the mutant channel was activated at lower membrane
potentials. At a given membrane potential, the mutant channel was activated
at lower calcium concentrations.
Taken together, results from electrophysiological studies in Xenopus
laevis oocytes and mammalian CHO cells indicate that the D434G mutation
leads to enhanced BK channel activation by increasing calcium sensitivity of
the RCK domain.

3.5 Discussion
Site-directed mutations of the BK channel were made to search for amino
acid residues that are important for calcium binding (73). Beside several
residues located in the calcium bowl, M513 near the RCK domain was
required to maintain the high-affinity response of the BK channel. M513I
resulted in a reduced calcium sensitivity (73), which is opposite to our findings
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Figure 9.

Electrophysiological characterization of wild-type and D434G

mutant channels in CHO cells. a) Single-channel currents recorded from WT
(left) and D434G mutant channels (right) expressed in CHO cells. At 5 µM
(upper traces) and 10 µM (lower traces) calcium concentration, the mutated
channel was more likely to be in the open state. There was no difference in
single channel conductance. C, closed state; O, open state; dotted lines zero current level. Membrane potential = +80 mV. b) Effect of membrane
potential on Popen of WT and mutant D434G channels at three calcium
concentrations (2, 10 and 50 µM). Lines are fits to the Boltzmann equation. c)
Relationship between calcium concentration, membrane potential, and Popen.
Each line is the Boltzmann fit obtained as in b. The difference between curves
becomes less at high calcium concentration, consistent with saturation of
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calcium binding. d) Relationship between Popen and calcium concentration at
membrane potentials of +60 mV (circles) and +80 mV (triangles) in WT and
mutant D434G channels. Lines are fits to the Hill equation. (b-d) solid lines,
wild-type; dashed lines, D434G mutant channels. n = 5-17 patches for each
point.
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that the D434G mutation increased calcium sensitivity of the BK channel. One
likely explanation is that different mutations result in different conformational
change of the BK channel. The conformational change induced by the D434G
mutation might favor calcium binding, while the M513I mutation might change
the channel conformation in a way that disfavors calcium binding. Structural
study may reveal the conformation of the RCK domain of the D434G mutant
channel.
It has been reported that calcium sensitivity of the BK channel α subunit
can be increased by association with the β subunit. Coexpression of the α
and the β subunits of mouse KCNMA1 in Xenopus laevis oocytes resulted in
increased sensitivity to calcium (74). Similar results were obtained in HEK
cells coexpressing the α and the β subunits. It was proposed that the β
subunit may increase some of the calcium binding rates in the open channel
states (75). A point mutation of human KCNMB1 encoding the β1 subunit of
the BK channel was identified in patients with hypertension. The mutation
resulted in an increased calcium sensitivity of the BK channel, without
changes in channel kinetics (76). Taken together, these results indicate that
the β subunits of the BK channel play a role in calcium binding. It is likely that
binding of the β subunits to the pore-forming α subunits changes the
conformation of the calcium-binding domain, thereby increasing calcium
sensitivity. It is unknown if coexpression of the D434G mutant channel with
different β subunits will further increase calcium sensitivity of the channel,
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compared with expression of the D434G mutant channel alone. A synergistic
effect on calcium sensitivity between the D434G mutation and the β subunits
might exist.
An increase in calcium sensitivity of the BK channel leads to greater
macroscopic potassium conductance under physiological conditions. Thus,
the D434G mutation results in a gain of function of the α subunit. There are
several reasons why gain of function of the BK channel could lead to an
increase in brain excitability, causing generalized epilepsy when the thalamus
or thalamocortical circuits are involved and paroxysmal dyskinesia when the
basal ganglia is involved. The most likely mechanism might be that the
D434G mutation leads to faster repolarization of the action potential.
Enhanced repolarization enables faster removal of inactivation of sodium
channels and thus allows neurons to fire at a higher frequency (77, 78).
Ethanol can activate the BK channel in C. elegans (79). This finding may
explain the observation that alcohol is one of the factors inducing paroxysmal
nonkinesigenic dyskinesia. The D434G mutation may have a synergistic
effect with ethanol to trigger the onset of GEPD.
In conclusion, results from the current study demonstrate that the D434G
mutation leads to a gain of function of the BK channel by increasing its
calcium sensitivity. It is still to be determined how the D434G mutation causes
increased calcium sensitivity of the BK channel.

51

CHAPTER IV
DISCUSSION AND FUTURE DIRECTIONS

The coexistence of epilepsy and paroxysmal dyskinesia in the same
individual or family is an increasingly recognized phenomenon. Previous
results indicated that the pericentromeric region on chromosome 16 is linked to
coexistent epilepsy and paroxysmal dyskinesia (44-48), but no specific gene
underlying the phenotype has been identified. By genotyping and linkage
analysis, we mapped a genetic locus associated with coexistent generalized
epilepsy and paroxysmal dyskinesia on chromosome 10q22. Markers
D10S580 and D10S1730 in this region showed significant linkage to GEPD
with lod scores of 3.68 and 3.73, respectively. The GEPD phenotype described
here differs from those linked to chromosome 16 in both the type of seizures
and paroxysmal dyskinesia expressed, and linkage to chromosome 16 was not
observed. The BK channel is important for neural transmission and muscle
contraction. Mice lacking the pore-forming α subunit of BK channel develope
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abnormal conditioned eye-blink reflex, impaired locomotion and motor
coordination, and high-frequency hearing loss (65, 66). Despite the important
physiological roles of BK channel, no mutation in the BK channel gene has
been associated with human diseases. We identified a D434G point mutation
in the RCK domain of the BK channel α subunit, which cosegregates with all
affected individuals in family QW1378, but is absent in all unaffected family
members and 500 unrelated healthy controls. Furthermore, D434 of KCNMA1
is evolutionally conserved among different species.
The RCK domain of the α subunit of BK channel has been reported to
contain binding sites for calcium and magnesium. We expressed wild-type
and D434G mutant BK channels in both Xenopus laevis oocytes and CHO
cells, and the results from electrophysiological studies indicate that the
primary effect of the mutation was to increase calcium sensitivity three- to
fivefold, which is consistent with the role of the RCK domain as a high-affinity
site for calcium binding. Increased calcium sensitivity might lead to neuronal
hyperexcitability in vivo by inducing rapid repolarization of action potentials,
resulting in GEPD by allowing neurons to fire at a faster rate.
Taken together, these results mapped a new genetic locus associated
with coexistent epilepsy and paroxysmal dyskinesia on chromosome 10q22
and established that mutations of the BK channel cause GEPD. This is the
first gene that has been associated with coexistent epilepsy and paroxysmal
dyskinesia. Our results have implications for the pathogenesis of human
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epilepsy, the neurophysiology of paroxysmal dyskinesia and the role of BK
channels in neurological disease.
Although epilepsy and paroxysmal dyskinesia are sometimes difficult to
differentiate clinically, the current understanding is that they are two distinct
disorders with some shared clinical features. The coexistence of epilepsy and
paroxysmal dyskinesia in the same individual or family has been reported (42,
43), but the basic pathophysiology underlying this neurological syndrome is
unknown, and no specific gene has been associated with it before this study.
Coexistence raises the possibility that a common, genetically determined
abnormality is variable expressed in the cerebral cortex and in basal ganglia
(80).
In the current work, we took advantage of genetic approaches to identify
mutated genes in patients affected by epilepsy and/or paroxysmal dyskinesia.
We carried out a genome-wide linkage scan with 382 fluorescent
microsatellite markers and found two of them, D10S580 and D10S1730 on
chromosome 10q22, are strongly linked to GEPD syndrome in the family we
studied. The lod scores (3.68 for D10S580 and 3.73 for D10S1730) are
higher than 3.0, which is considered as evidence for linkage (>99.9%). No
other markers showed a lod score of greater than 2.0, indicating that the
chromosome 10q22 region was the only region linked to GEPD in the family.
By fine mapping and haplotype analysis using eight additional markers, the
disease-associated interval was narrowed to a region of 8.4 cM on
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chromosome 10q22 flanked by markers D10S1694 and D10S201.
Subsequently, we searched the Celera database for genes located in the
8.4 cM region and selected candidate genes for mutational screening by
direct sequencing of all the exons. A D434G point mutation was identified in
the pore-forming α subunit of the BK channel. This mutation is present in all
the affected individuals in family QW1378, but is absent in normal family
members and 500 unrelated healthy controls, suggesting that it might
contribute to the pathogenesis of GEPD.
Syndromes of coexistent epilepsy and paroxysmal dyskinesia have been
reported, including autosomal dominant benigh infantile convulsions and
paroxysmal choreoathetosis (ICCA) (44) and related syndromes (46). The
ICCA phenotype is characterized by paroxysmal kinesigenic dyskinesia (PKD)
and generalized convulsions in infancy and has been linked to chromosome
16p, but the specific gene underlying the phenotype has not been identified
yet. The linkage to chromosome 16p was excluded by our linkage study in
family QW1378. One likely reason is that the GEPD phenotype described
here differs from ICCA in both the type of seizures and paroxysmal dyskinesia
expressed. The patients in family QW1378 were diagnosed as paroxysmal
nonkinesigenic dyskinesia (PNKD) which is induced by alcohol, caffeine,
fatigue and other factors, but not by sudden movement for PKD.
As discussed in Chapter I, mutations in over seventy genes have been
linked to different types of epilepsy, and many of these identified genes
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encode ion channels (Table I). Our finding of the BK channel mutation in
GEPD patients is consistent with the notion that ion channel defects play an
important role in the pathogenesis of epilepsy. Our results suggest that ion
channel dysfunction might also contribute to the pathogenesis of paroxysmal
dyskinesia.
It is likely that BK channel mutations are also associated with epilepsy
and/or paroxysmal dyskinesia in other sporadic patients or families. In order
to test this hypothesis, we screened BK channel mutations in another family
and 102 sporadic patients. However, we did not detect KCNMA1 mutations in
the patients we sequenced. One of the reasons might be that the phenotypes
of the patients differ from the GEPD patients. Most of them have either
epilepsy or paroxysmal dyskinesia, a few of them have migraine and
psychosis, and none of them has coexistent epilepsy and paroxysmal
dyskinesia. It is also likely that the mutations are present in different β
subunits of the BK channel which could either enhance or inhibit the function
of the α subunit. More patient samples will be needed to determine the
contribution of BK channelopathy to the pathogenesis of epilepsy and/or
paroxysmal dyskinesia.
Although BK channels play important roles in a variety of physiological
processes, no mutation in BK channel has been identified that is associated
with human diseases before this study. As described in Chapter II, we
identified a D434G point mutation in the RCK domain of the α subunit of the
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BK channel. In order to investigate how this mutation may lead to GEPD by
altering the function of the BK channels, we carried out electrophysiological
studies in both Xenopus laevis oocytes and CHO cells.
In oocytes, we found that there was more current induced at the same
membrane potential in cells expressing D434G mutant channels than in cells
expressing the wild-type channels, and the voltage dependence of
steady-state activation curve was shifted toward more negative potentials by
the D434G mutation. These results indicate that the mutant BK channel has
an increased voltage and calcium-dependent activation. Corresponding to the
shifts in voltage dependence of activation, the D434G currents activated
faster than the wild-type currents in response to a depolarizing voltage pulse.
These results suggest that during an action potential in neurons, in response
to depolarization and calcium entry through voltage-dependent calcium
channel, more mutant BK channels open, causing a rapid repolarization of
the action potential (72).
To define better the mechanism of the increase in macroscopic currents in
oocytes, we made single-channel recordings from BK channels expressed in
CHO cells. Both the wild-type channel and the D434G mutant channel were
activated by an increase in voltage or intracellular calcium concentrations, but
at a given voltage and calcium concentration, the mutant channel spent
substantially more time in the open state. At a given calcium concentration,
the mutant channel was activated at lower voltages. These date suggest that
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the primary effect of the mutation was to increase calcium sensitivity, rather
than to affect the voltage sensor, which is consistent with the role of the RCK
domain as a high-affinity site for calcium binding.
It has been reported that ethanol can directly activate the BK channel in
vivo in C. elegans (79). This finding may explain the observation that alcohol
triggers paroxysmal dyskinesia in certain individuals in the family reported
here and that alcohol is one of the factors that induces paroxysmal
nonkinesigenic dyskinesia. The ability of alcohol to trigger PNKD is well
recognized, but the detailed mechanism is still under investigation (81). The
gain-of-function mutation D434G may have a synergistic effect with ethanol to
trigger the onset of the syndromes.
Knockout mice deficient in the BK channel β4 subunit have been created
and characterized (67). The β4 subunit is a neuron-specific inhibitory subunit
which precludes the BK channel from contributing to the membrane
repolarization, resulting in prolonged action potentials and reduced firing
rates of neurons. Mice lacking the BK β4 subunit had a gain of function of BK
channels, increased firing rate of knockout cells and distinctive seizures
emanating from the temporal cortex. Treatment with paxilline, a specific
blocker for BK channels, reduced the firing rate. These results support our
conclusion that gain of function of the BK channel causes GEPD.
The in vivo physiological roles of KCNMA1 remain intriguing. Mice
homozygously deficient in KCNMA1 had abnormal conditioned eye-blink
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reflex and abnormal locomotion and motor coordination (65). These mice also
developed high-frequency hearing loss at eight weeks of age (66). The
phenotype of patients with the KCNMA1 mutation A1301G seems to be very
different from that reported for the knockout mice. One major reason for this
difference may be that the human missense mutation is a gain-of-function
mutation, whereas the mice lacked BK channels.
In summary, results from our electrophysiological studies and other
reports strongly suggest that gain of function of the BK channel may result in
generalized epilepsy and paroxysmal dyskinesia by allowing neurons to fire at
a faster rate.
As described in Chapter III, the D434G mutation increases the calcium
sensitivity of the α subunit, leading to a gain of function of the BK channel.
There are several reasons why gain of function of the BK channel could lead
to an increase in brain excitability, causing generalized epilepsy when the
thalamus or thalamocortical circuits are involved and paroxysmal dyskinesia
when the basal ganglia is involved. The most likely mechanism relates to the
more rapid repolarization of action potentials by D434G mutant channels.
Enhancing this repolarization enables faster repriming (removal of
inactivation) of sodium channels and thus allows neurons to fire at a higher
frequency (77, 78).
When cells are at rest, the intracellular potential is more negative with
respect to the extracellular potential. The potential difference is the resting
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membrane potential, which is about -70mV in many mammalian neurons. If
progressively larger depolarizing current pulses are applied to the cell
membrane, a threshold membrane potential can be reached at which an
action potential is triggered. An action potential is a rapid change in the
membrane potential followed by a return to the resting membrane potential.
An action potential can be divided into a depolarization phase, a
repolarization phase and a hyperpolarization phase (Figure 10).
In mammalian neurons, the action potential is triggered by successive
opening of sodium and potassium channels in the plasma membrane. When
a threshold membrane potential is reached by a depolarizing pulse, the
sodium channels open and the potassium channels remain closed. Because
the concentration of sodium ions is higher in extracellular fluid than in
cytoplasm, sodium ions flow into the cells through sodium channels in the
plasma membrane. The influx of positively charged sodium ions makes the
inner membrane more positive, resulting in the depolarization phase of an
action potential. The sodium conductance peaks at about the same time the
action potential peaks, and then the sodium channels begin to close (Figure
10). The potassium channels open more slowly than sodium channels and
peak at about the middle of the repolarization phase. Because the
concentration of potassium ions is higher in the cytoplasm than in
extracellular fluid, potassium ions flow out of the cells through the potassium
channels in the plasma membrane. The flow of potassium ions into
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Figure 10. A potential mechanism underlying gain of function of BK channel
and GEPD. An action potential is divided into a depolarization phase, a
repolarization phase and a hyperpolarization phase. The black curve
represents normal action potential. The blue curve represents the action
potential involving the D434G mutant BK channels.
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fluid results in the repolarization phase of an action potential. When the
membrane is returned to the resting membrane potential, all the sodium
channels are closed but some of potassium channels are still open. This
results in the hyperpolarization phase of an action potential which is more
negative than the resting membrane potential. The membrane returns to its
resting membrane potential when all potassium channels are closed. One
cycle of action potential persists for about 4ms (Figure 10).
An increase in calcium sensitivity of the D434G mutant BK channel leads
to

greater

macroscopic

potassium

conductance

under

physiological

conditions. At the same membrane potential and intracellular calcium
concentration, more mutant channels are likely to open compared with
wilt-type channels. Therefore, more potassium ions will flow into the
cytoplasm through the mutant BK channels than wild-type channels, resulting
in rapid repolarization of action potentials. Enhancing this repolarization
enables faster removal of inactivation of sodium channels and thus allows
neurons expressing the mutant BK channels to fire at a higher frequency.
There are some other reasons why enhancement of BK channels could
lead to GEPD. It is likely that enhancing some inhibitory currents can switch
neurons in a circuit into a bursting mode, as can occur with absence seizures
that depend on activation of inhibitory GABAB receptors in the thalamus (82).
Likewise, gain of function of BK channels could lead to greater
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hyperpolarization and activate the hyperpolarization-activated cation current,
resulting in generation of secondary depolarization (83). Another possible
explanation is that if BK channels are present in GABAergic neurons, an
increase in inhibition of these neurons could lead to disinhibition of a neuronal
network.
The studies described in this thesis identified a mutation in the BK
channel α subunit that is associated with human GEPD syndrome. These
studies lead to a compelling question regarding the role of BK channelopathy
in the pathogenesis of epilepsy and/or paroxysmal dyskinesia. Future studies
proposed here could address the question and further define how gain of
function of BK channels causes GEPD. Specifically, these studies include 1)
screening BK channel mutations in other patients with coexistent epilepsy
and paroxysmal dyskinesia, 2) investigation of the in vivo physiological role of
the mutant BK channel in D434G knockin rats, 3) studying the potential
synergism between the D434G mutation and the β1 subunit on calcium
affinity of the BK channel, 4) determining if the D434G mutation induces a
conformational change of the RCK domain.
Different mutations in a single gene could lead to similar pathological
phenotypes in patients of different families or populations. For instance, more
than twelve mutations of the sodium channel gene SCN1A have been
identified in patients affected by generalized epilepsy with febrile seizures
plus or severe myoclonic epilepsy of infancy. Therefore, it is likely that
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KCNMA1 mutations are present in other patients with clinical features that are
similar to GEPD in the family we studied.
Future studies will focus on mutational analysis of the twenty-seven
exons and adjacent introns of KCNMA1 using genomic DNA isolated from
patients with coexistent epilepsy and paroxysmal dyskinesia. The BK channel
β subunits genes (KCNMB1, KCNMB2, KCNMB3 and KCNMB4) are also
good candidates for mutation screening if mutations in KCNMA1 could not be
identified because the β subunits can either enhance or inhibit the function of
the α subunit. If different mutations are identified, electrophysiological studies
described in Chapter III will be performed to investigate how the mutations
may cause the disease. If BK channelopathy is proved to be a common cause
of coexistent epilepsy and paroxysmal dyskinesia, BK channel blocking
agents might be used as a potential therapy for this syndrome.
The in vitro studies described in Chapter III shed light on how the D434G
mutation might cause GEPD by enhancing the function of the BK channels,
but the functional effect of the mutation in vivo is still unknown. If the D434G
mutation results in GEPD in human, it might cause phenotypes of epilepsy
and/or paroxysmal dyskinesia in animals in which one allele of the normal BK
channel gene is replaced by human KCNMA1 with the mutation.
Rats are commonly used models for studies of epileptic phenotypes
because it is easier to record EEG in rats than in mice. Different types of cells
(neurons, smooth muscle cells, cardiomyocytes, etc) isolated from
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KCNMA1D434Gknockin rats and control rats will be used for single channel
recordings. The relationship between open channel probability and
membrane potential and calcium concentrations will be studied as described
in Chapter III. EEG will be recorded from thalamus of KCNMA1D434GKnockin
rats as described (86) to determine if there are spike-wave complexes which
are observed during epileptic seizures. It will also be examined if there is
abnormal movement of limbs in KCNMA1D434Gknockin rats treated with
alcohol, caffeine, and other factors that have been shown to induce
paroxysmal nonkinesigenic dyskinesia in human patients.
The BK channel core formed by four α subunits is necessary for basic
conduction function, and association of the core with different β subunits
(β1-β4) contributes to the molecular diversity of the BK channel. It has been
shown that the β1 subunit interacts with the S0 transmembrane domain and
increases the calcium affinity of the BK channel (84, 85), but the molecular
mechanism is not clear. Since studies described in Chapter III show that the
D434G mutation increases calcium affinity of the BK channel, it is likely that
the β1 subunit and the D434G mutation may increase calcium sensitivity in a
synergistic way.
Single channel conductance will be recorded in CHO cells expressing the
D434G mutant α subunit, wild-type α subunit plus β1 subunit, and D434G
mutant α subunit plus β1 subunit. The calcium affinity of each group will be
used to determine if a synergism exists between the D434G mutation and the
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β1 subunit.
The D434G mutation might induce conformational change of the RCK
domain in a way that favors binding of calcium. In order to test this hypothesis,
we can purify the mutant RCK domain for structural studies. Because it is
technically demanding to purify the whole BK channel, we cloned only the
wild-type and mutant RCK domain into His-tagged vector and expressed
them in E.coli. Although we tried a variety of conditions such as growing E.coli
at low temperatures, we were unable to obtain native proteins due to the
formation of inclusion bodies through interaction of the hydrophobic regions.
An alternative way to obtain soluble native proteins is to express the RCK
domain in insect cells where nascent proteins will undergo posttranslational
modifications. Posttranslational modifications facilitate proper folding of the
proteins which may be soluble with the hydrophobic domains surrounded by
the hydrophilic domains. The structure of the mutant RCK domain can be
determined by X-ray crystallography.
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CHAPTER V
ANGIOGENIC EFFECT OF AGGF1

5.1 Introduction
Blood vessels carry oxygen and nutrients required for normal tissue
function throughout our bodies. Angiogenesis, the formation of new blood
vessels from the preexisting ones, is a fundamental biological process. In the
embryo, blood vessels form through vasculogenesis, a process during which
angioblasts differentiate into endothelial cells, which further assemble into a
primitive vascular network. In the adult, blood vessel formation occurs under
both physiological and pathological conditions (e.g. wound healing, ischemia,
etc). Angiogenesis is regulated by an interplay of pro- and anti-angiogenic
molecules, and their imbalance could lead to various diseases. For instance,
excessive angiogenesis is present in tumors, while insufficient angiogenesis is
associated with conditions such as coronary heart disease and stroke.
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Unraveling the molecular mechanisms of angiogenesis will help define
specific targets for therapeutic intervention.
Vasculogenesis is the process of blood vessel formation in which
angioblasts migrate to specific locations and differentiate into endothelial cells
which form a primitive vasculature. Vasculogenesis first occurs in the yolk sac
blood island of the developing embryo. Within the blood island,
hemangioblasts (87), the common precursor for both hematopoietic cells and
endothelial cells, differentiate into hematopoietic precursor cells and
angioblasts. Several molecules have been implicated in the regulation of
hemangioblast differentiation, but the molecular signals are not fully
elucidated (88). VEGFR-2 is likely to play an important role at this
developmental stage, as mice lacking the receptor failed to develop both
hematopoietic and endothelial cell lineages (89).
Angioblasts derived from hemangioblasts migrate to the paraxial
mesoderm of yolk sac and differentiate to form a primary capillary plexus.
Vasculogenesis was first believed to occur only in the developing embryo.
However, it was recently realized that vasculogenesis can also occur
postnatally. Circulating bone-marrow derived angioblasts in the adult were
identified and able to contribute to neovascularization under conditions such
as tumor growth and cardiac ischemia (90-92).
Vasodilation of existing blood vessels is one of the earliest steps in
angiogenesis. Vasodilation is accompanied by degradation of extracellular
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matrix and an increase in vascular permeability, which allows activated
endothelial cells to migrate to distal sites where they assemble to form
lumens.
Vascular permeability is mediated by VEGF in response to nitric oxide
(93). The vascular permeability activity of VEGF is dependent on Src family
kinases (SFKs), as mice deficient in Src or Yes showed no VEGF-induced
vascular

permeability

(94).

Increased

vascular

permeability

allows

extravasation of plasma proteins that create a provisional scaffold for
subsequent migration of activated endothelial cells. Vascular permeability is
negatively regulated by Angiopoietin-1 (Ang1) that is a ligand for the
endothelial cell-specific receptor Tie2 (95). Ang1 protects the vasculature
against excessive plasma leakage, which could result in pathological
conditions such as intracranial hypertension and circulatory collapse.
Extracellular matrix must be degraded to free angiogenic factors that are
trapped within the matrix and to clear the path for endothelial cells to migrate
to distal sites. Many proteinases are involved in this process and matrix
metalloproteinases (MMPs) play a central role in degrading extracellular
matrix (96). Other proteinases, such as urokinase-type plasminogen activator
(u-PA), have also been implicated in matrix degradation (97, 98).
After the extracellular matrix is degraded by proteinases, proliferating
endothelial cells are able to migrate to distal sites to assemble into new
vessels. VEGF and its homologues play a major role in this step (99, 100).
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VEGF induces endothelial cell proliferation through PLC-γ signaling pathway
and migration by activating PI3K or FAK. Placental growth factor (PIGF),
although

dispensable

for

embryonic

vasculogenesis,

amplifies

VEGF-dependent angiogenesis in the adult (101). VEGF-B and VEGF-C are
also involved in endothelial cell proliferation and migration (102, 103).
Beside VEGF and its homologues, several additional molecules have
also been implicated in this process. Fibroblast growth factor (FGF)-1 plays
an important role in the branching and growth of the coronary arteries, as
revealed by studies in FGF-1 transgenic mice (104). Endothelial nitric oxide
synthase (eNOS) promotes vessel growth in ischemic hindlimb of mice (105).
Transforming growth factor (TGF)-β1 inhibits angiogenesis in tumors (106),
and VEGF-induced endothelial cell proliferation is impaired by tumor necrosis
factor (TNF), which inhibits the phosphorylation and activation of VEGFR-2
(107). Integrins expressed on the surface of activated endothelial cells
regulate endothelial adhesion to the extracellular matrix, which is important
for endothelial cell proliferation and migration (108, 109).
Endothelial cells often assemble into solid cords that subsequently
acquire a lumen. The length of new blood vessels increases as they fuse with
existing vessels. Tumor vessels are structurally distinct from normal vessels
in that they are tortuous and dilated with excessive branching. Lumen
formation is mainly regulated by VEGF and Ang1 (110), and several integrins
are also involved in this process (111).
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Endothelial cells become quiescent once new vessels have been
assembled and reduced endothelial survival results in vessel regression.
VEGF mediates endothelial survival by activating the PI3K/Akt signaling
pathway which is further enhanced by VE-cadherin via formation of a
multicomponent complex between VE-cadherin, β-catenin, PI3K and
VEGFR-2 (112). Ang1 also activates Akt by binding to the Tie-2 receptor and
causes increased expression of the apoptosis inhibitor survivin (113). In
contrast, Ang2 suppresses endothelial survival in tumors (114). Disruption of
interaction between endothelium and extracellular matrix by αvβ3 inhibitor
results in endothelial apoptosis, but adult quiescent blood vessels are
unaffected as αvβ3 is only expressed in proliferating cells (115). Endothelial
apoptosis can also be induced by some other molecules, including
angiostatin, TSP-1, the metallospondin METH-1 and vascular endothelial
growth inhibitor.
Maturation of nascent blood vessels involves recruitment of mural cells
and development of surrounding matrix which are regulated by a variety of
molecules. Mural cells generally refer to as vascular smooth muscle cells and
pericytes, both involved in the formation of normal vasculature and
responsive to VEGF. PDGFB deficient mice lack pericytes in certain vessels
which leads to endothelial hyperplasia, increased capillary diameter and
abnormal vascular morphogenesis, indicating that PDGFB signaling through
PDGFR-β expressed on mural cells play a role in recruitment of pericytes to
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newly formed vessels (116). The phenotypes of EDG1 knockout mice are
similar to those of PDGFB deficient mice, suggesting that signaling through
EDG1 receptor is another pathway for mural cell recruitment (117). The lack
of EDG1 receptor may alter the interaction between endothelial cells and
mural cells and interfere with vessel maturation. There might be a crosstalk
between the PDGF and EDG receptor signaling involved in mural cell
recruitment,

as

PDGFR-β-deficient

mice

showed

markedly

reduced

expression of RGS5, a molecule downstream of EDG receptor (118, 119).
Ang1 is known to stabilize nascent vessels and make them less leaky.
Recombinant Ang1 restored an organized vasculature and rescued retinal
edema and hemorrhage in the absence of mural cells in the retina of mouse
neonates (120), suggesting that Ang1 may not be involved in interaction
between endothelial cells and mural cells as suggested previously. The role
of Ang2 seems to be dependent on VEGF. In the presence of VEGF, Ang2
promotes angiogenesis. In the absence of VEGF, Ang2 acts as an antagonist
of Ang1 which destabilizes blood vessels and leads to vessel regression.
TGF-β1 plays a role in the establishment and maintenance of vessel wall
integrity by promoting extracellular matrix protein deposition and by inducing
differentiation of mesenchymal cells into mural cells (121, 122).

The

TGF-β1-ALK5 signaling pathway induces the plasminogen activator inhibitor
1 which promotes vessel maturation by preventing degradation of
extracellular matrix surrounding the nascent vessels. Mice deficient of
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Endoglin, a TGF-β-binding protein, showed impaired vascular remolding and
differentiation of smooth muscle cells (123).
5.2 Angiogenesis and Angiogenic Factors
VEGF is a key regulator of physiological angiogenesis during embryonic
development and pathological angiogenesis associated with tumors,
ischemia and other conditions (124). VEGF denotes a family of homodimeric
glycoproteins, which consists of five mammalian (VEGF-A, VEGF-B, VEGF-C,
VEGF-D, and PIGF) and one virus-encoded member (VEGF-E). They bind to
three

structurally

homologous

tyrosine

kinase

receptors

(VEGFR-1,

VEGFR-2 and VEGFR-3) in an overlapping pattern (125). Ligand binding
induces receptor dimerization and autophosphorylation and, thereby,
transduction of signals that regulate cellular function (126). There are also
accessory receptors such as neuropilins which enhances the binding of
VEGF to VEGFR-2 and VEGF-mediated mitogenic activity for endothelial
cells (127).
Disruption of a single VEGF allele in mice resulted in a lethal impairment
of vasculogenesis (128, 129), and overexpression of VEGF led to severe
abnormalities in heart development and embryonic lethality (130), indicating
that VEGF dosage must be tightly regulated to avoid vascular abnormalities.
VEGF is also required for angiogenesis in neonatal mice, as evidenced by
VEGF inactivation by conditional knockout or by administration of soluble
VEGF receptors (131). VEGFR-2 seems to be the major mediator of the
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growth and permeability effects of VEGF on vascular endothelial cells. Mice
lacking VEGFR-2 failed to develop a functional vasculature and had very few
endothelial cells (132). Taken together, these results demonstrate a critical
role of VEGF-VEGFR-2 signaling in angiogenesis.
There is increasing evidence that VEGFR-1 may function as a negative
regulator of VEGFR-2. Normal vascular development was disrupted by the
loss of VEGFR-1 due to obstruction of blood vessels by excessive endothelial
cells (133), but deletion of its tyrosine kinase domains did not affect
embryonic angiogenesis (134), indicating the role of VEGFR-1 as a decoy
receptor that binds to VEGF and thereby controls the amount of VEGF
available for VEGFR-2. Such a decoy function might be explained by the
soluble form of VEGFR-1 which contains the extracellular ligand-binding
domains, but lacks the intracellular tyrosine kinase domains (135).
Overexpression of the soluble VEGFR-1 inhibits VEGF-induced migration
and proliferation of endothelial cells by forming an inactive complex with
VEGF (136).
VEGFR-3 is a high-affinity receptor for VEGF-C and VEGF-D, and
activation of VEGFR-3 induces proliferation, migration and survival of
lymphatic endothelial cells (137). VEGF-B deficient mice had smaller hearts,
suggesting that it might be involved in coronary vascularization and growth
(102). VEGF-E is a VEGFR-2-specific ligand encoded by sheep parapoxvirus
(138), and transgenic mice overexpressing VEGF-E showed a dramatic
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increase in vascularization (139). PIGF deficient mice were healthy and fertile
and vascular development in embryos was normal. However, PIGF deficiency
impaired VEGF-dependent angiogenesis under pathological conditions such
as ischemia and wound healing (140, 141). It is likely that PIGF enhances the
activity of VEGF by displacing VEGF from VEGFR-1, thereby increasing the
amount of VEGF available to activate VEGFR-2.
Despite the requisite role of VEGF in angiogenesis, some other factors
are also involved in this process. The angiopoietin family of proteins, such as
Ang1 and Ang2, bind to the Tie receptors that are specifically expressed
within the vascular endothelium (142, 143). Mouse embryos lacking Tie-1
failed to establish structural integrity of vascular endothelium resulting in
oedema and local haemorrhage, and Tie-2 deficient embryos displayed
impaired vascular network formation in endothelial cells (144). Ang1 knockout
mice developed a rather normal vasculature during embryogenesis, but this
vasculature failed to undergo further remolding processes. In the heart, it was
observed that endothelial cells failed to associate appropriately with
underlying supporting cells. This finding led to the suggestion that Ang1 plays
an important role in mediating reciprocal interactions between the
endothelium and surrounding matrix and mesenchyme (145). Vessels in
Ang1-overexpressing mice were resistant to leak induced by VEGF or
inflammatory agents. This is probably due to the ability of Ang1 to enhance
interactions between endothelial cells and their surrounding matrix, as
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vessels overexpressing Ang1 were resistant to treatments that normally
created holes in the endothelial cell barrier (146). Overexpression of Ang2,
another ligand for Tie2, disrupted blood vessel formation in the mouse
embryos, indicating that Ang2 is an antagonist for Tie2 (147). Analysis of
Ang2 deficient mice indicated that Ang2 is dispensable for embryonic
vascular development but is required for postnatal angiogenic remolding
(148).
Ephrin-B2 and its EphB4 receptor also play important roles during
vascular development (149). Ephrin-B2 is expressed in arterial but not
venous endothelial cells, while EphB4 marks veins but not arteries,
suggesting that a reciprocal signaling exists between these two types of
vessels (150). Mouse embryos lacking ephrin-B2 showed fatal defects in
remolding of the embryonic vascular system that are similar to those seen in
mice deficient of Ang1 or Tie2 (151).

As development proceeds, ephrin-B2

expression extends from the arterial endothelium to surrounding smooth
muscle cells and pericytes, suggesting that ephrin-B2 might play a role in the
interaction between arterial endothelial cells and mural cells (152, 153).
AGGF1 (angiogenic factor with G patch and FHA domain 1) is a novel
angiogenic factor identified by a genetic study of Klippel-Trenaunay syndrome
(KTS) (154). AGGF1 contains 714 amino acids with a forkhead-associated
(FHA) domain and a G-patch domain. FHA domains are conserved
sequences of 65-100 amino acids found primarily within nuclear proteins. It
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was shown that the FHA domain mediates protein-protein interactions
through its phosphopeptide recognition motif (155). The G-patch domain is
found in many eukaryotic proteins and it is often associated with RNA-binding
(156).
AGGF1 is expressed in cells involved in angiogenesis, including
endothelial cells and vascular smooth muscle cells. Purified AGGF1
promoted blood vessel formation in the chicken embryos similar to VEGF, and
the E133K mutation identified in KTS patients further enhanced the
angiogenic effect of AGGF1. Consistent with this finding, knockdown of
AGGF1 by siRNA inhibited tube formation by endothelial cells plated on
matrigel (154). AGGF1 was able to bind to cultured endothelial cells as shown
by cell adhesion assays. It is not clear, however, whether AGGF1 acts on
endothelial cells in an autocrine fashion or a paracrine fashion as AGGF1 is
also expressed by vascular smooth muscle cells. Besides, the receptor for
AGGF1 remains to be determined (154). TWEAK is a member of the tumor
necrosis factor (TNF) superfamily which has multiple biological activities,
including stimulation of cell growth and angiogenesis (157).

TWEAK

treatment induced proliferation of a variety of human endothelial cells and
aortic smooth muscle cells (158). AGGF1 was found to interact with TWEAK
by yeast two-hybrid analysis and co-immunoprecipitation assays, and the
direct physical interaction between AGGF1 and TWEAK was demonstrated
by GST pull-down assays, suggesting that AGGF1 may promote
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angiogenesis by interacting with TWEAK (154). Taken together, these results
strongly suggest that AGGF1 is a pro-angiogenic factor.
A recent report showed that AGGF1 is a chromatin-associated protein
required for β–catenin-mediated transcription and AGGF1 expression was
increased in colon tumors, suggesting a role of AGGF1 in tumor angiogenesis
(159). The in vivo angiogenic effects of AGGF1 remains to be investigated in
genetically engineered animal models such as AGGF1 transgenic and
knockout mice. Future work on AGGF1 may have important therapeutic
implications in treatment of angiogenesis related disorders such as wound
healing, ischemic heart disease and cancer.

5.3 Klippel-Trenaunay Syndrome
As discussed in the previous section, AGGF1 is an angiogenic factor
involved in the pathogenesis of Klippel-Trenaunay syndrome. A chromosome
translocation was identified in a patient affected by KTS and increased
AGGF1 expression by 3-fold. We will discuss the clinical features and
genetics of KTS in this section.
Klippel-Trenaunay Syndrome (KTS) is a congenital vascular disorder
characterized by capillary and venous malformations, extensive distribution of
varicose veins and hypertrophy of affected tissues (160, 161). Capillary
malformations are the predominant phenotypes of KTS and occur in 98% of
the KTS patients. The walls of the capillaries are thin and the endothelial cells
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are flat (162). Capillary malformations are sometimes accompanied by
venous and lymphatic malformations. Varicose veins account for 72% of the
KTS patients (163), which is characterized by dilation, duplication and
external compression of veins (164). Limb hypertrophy is present is 67% of
KTS patients, and usually involves the lower extremities (163). Hypertrophy
can also occur in other parts of the body such as abdomen, head and neck.
Both sporadic and familial cases of KTS have been reported (165, 166). A
study of a patient with KTS phenotype and developmental delay and minor
anomalies

identified

a

reciprocal

translocation

t(5;11)(q13.3;p15.1),

suggesting a gene responsible for this syndrome might be located to
chromosome

5q

or

11p

(167).

Another

balanced

translocation

t(8;14)(q22.3;q13) was identified a patient with a vascular and tissue
overgrowth syndrome consistent with KTS (168). A de novo supernumerary
ring chromosome derived from chromosome 18 was identified in a patient
with KTS and mild mental retardation (169). The identification of three
different cytogenetic abnormalities in KTS patients suggest that several
different genes may be involved in different cases of KTS. As discussed
before, the 5q13.3 breakpoint was found to be located in the promoter region
of AGGF1 and increased the expression of AGGF1 (154). The breakpoints for
translocation t(8;14)(q22.3;q13) have been mapped to a 5cM interval on
chromosome 8q22.3 and a 1cM interval on chromosome 14q13, but no
specific gene has been identified yet (168).
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The finding that KTS translocation increases AGGF1 expression
suggests that enhanced angiogenesis contributes the pathogenesis of KTS.
This is consistent with the increased number and diameter of the venules and
defects in the process of vascular growth and remodeling revealed by
magnetic resonance imaging (MRI) (170, 171).
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CHAPTER VI
AGGF1 TRANSGENIC MICE

6.1 Abstract
AGGF1 has been shown to promote angiogenesis in vitro, but its in vivo
angiogenic effects remain to be investigated. Here we report the generation of
AGGF1 transgenic mice using a 2-kb promoter/regulator of the human AGGF1
gene that showed transcriptional activity by a luciferase assay. The integration
of the transgene into the mouse genome was examined by PCR and Southern
blot analysis and four positive lines were identified. Unfortunately, no
transgene expression was detected by both methods. One likely explanation
for this problem is that although the 2-kb promoter/regulator showed
transcriptional activity in a sensitive luciferase assay, it might be missing some
important enhancer segments that are required for robust transcription in vivo.
Therefore, it might be better to use a longer promoter fragment up to 8kb, as
98% of known binding sites for mammalian transcription factors occur within
8kb of target genes (172). Alternatively, the Tie-2 promoter could be used to
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drive endothelial cell-specific expression of human AGGF1. The Tie-2
promoter has been reported to successfully drive expression of various
human genes in transgenic mice, but it might cause loss of phenotypes
because AGGF1 is expressed not only in endothelial cells but also vascular
smooth muscle cells which are also involved in angiogenesis.

6.2 Introduction
Blood vessels deliver oxygen, nutrients, molecules and cells to all tissues
in our body. Small blood vessels consist only of endothelial cells, whereas
larger vessels are covered by pericytes and smooth muscle cells.
Angiogenesis, the process of growing new blood vessels from the existing
vasculature, is essential for organ growth in the embryo and repair of
wounded tissue in the adult (173). Angiogenesis is regulated by an interplay
of pro- and anti-angiogenic molecules such as VEGFs, angiopoietins and
ephrins. If angiogenesis is not properly regulated, it contributes to a number
of diseases including cancer, arthritis, stroke and coronary heart disease.
Understanding the molecular basis of angiogenesis will have important
therapeutic implications. For example, it will be possible to treat ischemic
heart disease by stimulating myocardial angiogenesis and cure cancer or
inflammatory disorders by inhibiting excessive vessel growth.
AGGF1 is a newly identified protein and there is strong evidence that
AGGF1 is a pro-angiogenic factor. AGGF1 is expressed in endothelial cells
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and vascular smooth muscle cells, two major components of blood vessels.
Purified AGGF1 promoted blood vessel formation in the chicken embryos
similar to VEGF, and knockdown of AGGF1 by siRNA inhibited tube formation
by endothelial cells plated on matrigel (154). Furthermore, AGGF1 was able
to bind to cultured endothelial cells as shown by cell adhesion assay (15).
Moreover, AGGF1 was shown to interact with TWEAK directly (154). TWEAK
is a member of the tumor necrosis factor (TNF) superfamily which has
multiple biological activities, including stimulation of cell growth and
angiogenesis (157). Despite these findings, the in vivo angiogenic effects of
AGGF1 remain to be investigated.
Here we report the generation and genotyping of AGGF1 transgenic mice.
The integration of human AGGF1 into the genome of transgenic mice was
confirmed but AGGF1 expression could not be detected by both RT-PCR and
Western blot analysis.

6.3 Materials and Methods
The AGGF1 transgene is composed of a 2kb promoter/regulator of
human AGGF1, a 2.1kb human AGGF1 cDNA and a 600bp human growth
hormone (HGH) Poly A. The promoter/regulator region was amplified from
genomic DNA by PCR using primers 5’-TGCTGGGCCCTGAGAGAGGAG-3’
and 5’-TATACTCGAGGAGCTCCGGCG-3’. The PCR product was purified
from agarose gel, digested with enzymes ApaI and XhoI, and cloned into

83

vector pcDNA3.1(-) digested with ApaI and XhoI. The human AGGF1 cDNA
was

amplified

from

pET-28VG5Q

(Novagen)

using

primers

5’-TTCGGCTACAAGTGAGTTTC-3’ and 5’-GAAGGACACCTAGTCAGAC-3’.
The PCR fragment was purified and cloned into promoter-pcDNA3.1 using
enzymes NotI and BamHI. The HGH-Poly A was amplified from Clone 26 (a
generous gift from Dr. Jim Gulick, University of Cincinnati Medical Center)
using

primers

5’-ATATGGATCCGGGTGGCATCCCTGTG-3’

and

5’-TATACCTAGGAACAGGCATCTACTGAG-3’. The PCR fragment was
cloned into promoter-cDNA-pcDNA3.1 using BamHI. The full-length construct
including the promoter/regulator, cDNA, HGH-Poly A and pcDNA3.1(-) vector
was verified by direct sequencing and no mutation in the transgene was found.
The construct was digested by PmeI to generate the transgene that was used
for injection into the pronuclei of fertilized mouse eggs at the Case Transgenic
and Targeting Core.
The mouse endothelial cell lines bEnd3 (established from cerebral cortex
of adult mouse brain) and C166 (established from yolk sac of mouse embryo)
(ATCC, Manassas, VA) were maintained in Dulbecco’s modified Eagle’s
medium (DMEM) containing 10% fetal bovine serum. Cells were cultured at
37 ℃ in a humidified atmosphere with 10% CO2.
Luciferase reporter assays were performed as described (174). Briefly,
bEnd3, C166 and human umbilical vein endothelial cells (HUVEC) were
seeded into six-well plates and grown to about 70% confluence. Each well
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was cotransfected with 0.9 μg of pGL3-Basic plasmid (Promega) or 0.9 μg of
AGGF1(P)-Luc and 0.1 μg of pRL-SV40 plasmid (Promega) using
Lipofectamine 2000 (Invitrogen). AGGF1-Luc contains a 2-kb fragment of
human AGGF1 promoter/regulator cloned before the luciferase gene of
pGL3-Basic. Plasmid pRL-SV40 contains the renilla luciferase gene driven by
an SV40 promoter and was cotransfected for normalization. Cells were
harvested 24 hours after transfection followed by lysis with passive lysis
buffer (Promega). The luciferase activities were measured with the
Dual-Luciferase Reporter Assay System (Promega) using a luminometer and
normalized by the renilla luciferase activity after subtraction of background.
All experiments were performed in triplicates.
Transgenic mice of B6/SJL background were used for genotyping by PCR.
Mouse tail tips were isolated from new pups of 4-week old and added to 50 μl
of lysis buffer (50 mM Tris-HCl, pH 8.0, 10 mM EDTA, 50 mM NaCl, 0.25%
SDS, 0.5 mg/ml Proteinase K). The samples were incubated overnight at
55 ℃ with shaking and diluted in 900 μl H2O followed by centrifugation at
maximal speed for 10 minutes at 4 ℃. The supernatant was collected and
used for subsequent PCR. Two pairs of primers were used for PCR: 1)
5’-CTGAAATTACTGATAGCAAC-3’ and 5’-GAAGGACACCTAGTCAGAC-3’,
2)

5’-TGGTTTTCCGACTGCTTATC-3’

and

5’-TTCTCCACCTTCCGCCTTAG-3’. Primer 1 amplifies a 431-bp fragment
that includes a portion of human AGGF1 cDNA and HGH poly A. Primer 2
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amplifies a 274-bp fragment that includes part of the promoter/regulator
segment and the AGGF1 cDNA. The PCR products were resolved on an
agarose gel.
The founder mouse lines that are positive by PCR genotyping were
verified by Southern blot analysis as described (175). 10 μg of genomic DNA
samples from mouse tails were digested with enzymes ApaI and EcoRI and
separated on a 0.7% agarose gel overnight at 30 volts. The gel was then
denatured in 0.5 N NaOH solutions and DNA was transferred onto a Hybond
N+ nylon membrane (Amersham).

Membranes were prehybridized with

hybridization buffer (50% formamide, 6x SSPE, 5x Denhardt's reagent, 0.5%
SDS, 100 μg/ml Salmon Testes DNA) for 1 hour at 42 ℃. The probe that
hybridizes to the promoter/regulator fragment of the transgene was amplified
by

primers

(5’-ATGATCTAATTCTAAATGAC-3’

5’-AACTGTCCTATAGAACTGATG -3’) and labeled with

32

and

P using the

Random Primer Labeling Kit (Stratagene) according to the manufacturer’s
instruction. The denatured probe was used for hybridization overnight at
42 ℃ in hybridization oven. The membrane was washed several times before
detection by autoradiography.
Total RNA was isolated from different mouse tissues, including the heart,
lung, liver, spleen, kidney, brain and embryo, using RNAeasy kit (Qiagen, CA)
according to the manufacturer’s instructions. The isolated total RNA was
digested with DNase at room temperature for 30 minutes to remove potential
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genomic DNA contamination. The samples were then reverse transcribed to
cDNA by reverse transcriptase. The primers for the reverse transcription step
are oliga dT and the oligonucleotide (5’-GAAGGACACCTAGTCAGAC-3’) that
is complementary to a HGH poly A sequence. The cDNAs were then
amplified by PCR using primers and conditions that are the same as
described above for genotyping. Mouse β-actin was used as reverse
transcription control (the primers were supplied in the RNAeasy kit).
Total proteins were extracted from different mouse tissues stored at a
-70°C freezer as described (176). Briefly, mouse tissues were removed from
a –70 °C freezer, weighed before thawing, and kept on dry ice. While the
samples were still frozen, 800-1000 μl of lysis buffer (1M Tris-HCl pH 8.0, 5M
NaCl, 0.1M EDTA, 10% NP-40) were added to each sample (protease
inhibitors were added to lysis buffer before use) and the samples were kept
on ice for 5 minutes. The samples were then homogenized for 20 seconds
and put on ice to keep them cool. This step was repeated 3 to 5 times until the
samples were well homogenized. The samples were then kept on ice for 20
minutes followed by centrifugation at 13,000 g at 4 °C for 20 minutes. The
supernatant was collected and the protein concentration was measured using
absorbance at 280 nm.
For Western blot analysis, the primary antibody we used was a rabbit
anti-human AGGF1 antibody (1:500) and the secondary antibody was
anti-rabbit IgG-HRP (1:3000). Glyseraldehyde-3-phosphate dehydrogenase
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(GAPDH) was used as a loading control.

6.4 Results
The structure of the transgene used for generating transgenic mice
overexpressing human AGGF1 is shown in Figure 11a. The transgene cloned
in the pcDNA3.1(-) vector is composed of a 2-kb promoter/regulator fragment
of human AGGF1 gene, a 2.1-kb human AGGF1 cDNA and a 600-bp human
growth hormone (HGH) poly A. the promoter/regulator was used to drive
endogenous expression of AGGF1 and HGH poly A was used to stabilize
nascent mRNA and facilitate translation (177, 178). The enzymes used for
cloning is indicated in Figure 11a.
The promoter activity of the 2-kb promoter/regulator fragment of human
AGGF1 gene was examined by a luciferase reporter assay. The relative
luciferase activity was measured in human endothelial cell line (HUVEC) and
mouse

endothelial

cell

lines

(bEnd3

and

C166)

transfected

with

AGGF1(P)-Luc containing the 2-kb promoter/regulator fragment. The
fragment showed promoter activity in both human and mouse endothelial
cells after subtraction of background activity generated by the pGL3-Basic
plasmid and normalization (Figure 11b). These results indicate that the
promoter/regulator fragment of human AGGF1 gene is likely to drive AGGF1
expression in transgenic mice. The ~4.7-kb transgene was released from the
pcDNA3.1 plasmid by digesting with the restriction enzyme PmeI and was
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used for injection into mouse fertilized eggs at the Case Transgenic and
Targeting Core.

Ten lines, eighty-six founder mice of B6/SJL background

were generated at the Case Transgenic and Targeting Core. No obvious
defects were found in these mice as examined by eyes. Genomic DNA was
isolated from the mouse tails and transgene integration was examined by
PCR using two pairs of primers. One primer amplifies a 431-bp fragment
spanning the promoter and the cDNA and the other primer amplifies a 274-bp
fragment including a portion of cDNA and HGH poly A. Clear bands were
detected in AGGF1 positive mice, but not in nontransgenic mice, using both
primers (Figure 12a).
By PCR genotyping, four positive founder lines (lines 2, 5, 8, 9) were
identified, which were further confirmed by Southern blot analysis. Genomic
DNA was digested by the enzymes ApaI and EcoRI to release a 2.7-kb
fragment including the 2-kb promoter/regulator and part of the cDNA. A
~800-bp probe was designed to hybridize to the promoter/regulator fragment
(Figure 11a). A 2.7-kb band representing the transgene was detected in all
four positive lines but not in nontransgenic mice (Figure 12b).
The four positive mouse lines were used to examine AGGF1 expression
by RT-PCR and Western blot analysis. AGGF1 total RNA and proteins were
isolated from various tissues, including the heart, lung, liver, spleen, kidney,
brain and embryo. Several pairs of primers were used for RT-PCR, but an
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Relative Luciferase Activity
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HUVEC

bEnd3

C166

AGGF1-p-Luc

HUVEC

bEnd3

C166

PGL3-basic

Figure 11. Generation of AGGF1 transgene. a) The AGGF1 transgene
contains a 2-kb promoter/regulator fragment of human AGGF1 gene, a 2.1-kb
human AGGF1 cDNA and a 600-bp HGH poly A. the transgene is released by
PmeI and used for zygote injection. The probe is used for Southern blot. b)
The 2-kb promoter/regulator fragment displayed promoter activity by a
luciferase reporter assay. The relative luciferase activities of the fragment in
human endothelial cell line (HUVEC) and mouse endothelial cell lines (bEnd3
and C166) transfected with AGGF1(P)-Luc were shown. The background
activities were measured by transfecting cells with the pGL3-Basic plasmid.
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Figure 12. Genotyping of AGGF1 transgenic mice. a) Genotyping by PCR.
Primer 1 amplifies a 431-bp fragment that spans the promoter and cDNA in
positive mice. Primer 2 amplifies a 274-bp fragment that spans the cDNA and
HGH poly A in positive mice. No bands were detected in negative mice. b)
Genotyping by southern blot. A 2.7-kb fragment representing the transgene
was detected in four positive founder lines (2, 5, 8, 9), but not in
nontransgenic mice (NT).
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Figure 13. AGGF1 expression in transgenic mice. a) RT-PCR analysis. An
expected band was not detected in lane 1. b) Western blot. No increased
expression of AGGF1 was detected in AGGF1 transgenic mice.
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expected band in lane 1 could not be detected (Figure 13a). RT-PCR results
were confirmed by Western blot analysis. The antibody recognizes both
human and mouse AGGF1, but an expected increase in band intensity at lane
1 and lane 2 was not detected (Figure 13b). These results indicate that
AGGF1 was not expressed in the transgenic mice.

6.5 Discussion
The results from previous in vitro studies on AGGF1 indicate that it is a
novel angiogenic factor (154). In order to investigate the role of AGGF1 in
blood vessel formation in vivo, we generated transgenic mice overexpressing
human AGGF1 under the control of a 2-kb promoter/regulator fragment of
human AGGF1 gene. The purpose of using the promoter/regulator fragment
is to mimic endogenous expression of AGGF1.
Integration of transgene into the genome of transgenic mice was
confirmed by PCR and Southern blot analysis in four founder lines. The
expression of AGGF1 in various tissues was examined by RT-PCR and
Western blot analysis, but unfortunately, no AGGF1 expression could be
detected.
One possible reason for this problem is that the 2-kb promoter/regulator
fragment of human AGGF1 might be missing some important enchancer
segments that are required for robust transcription in vivo, although the
promoter/regulator fragment showed transcriptional activity in a luciferase
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reporter assay which is very sensitive. Therefore, a longer promoter fragment
up to 8kb could be used to drive transgene expression in transgenic mice, as
98% of known binding sites for mammalian transcriptional factors are located
within a 8kb region of target genes. An alternative method would be to use the
Tie-2 promoter to drive endothelial cell-specific expression of AGGF1
transgene. Tie-2 promoter has been shown to successfully drive expression
of various human genes in transgenic animal models, but it could potentially
result in loss of phenotypes in transgenic mice because AGGF1 is expressed
not only in endothelial cells but also in smooth muscle cells which are
involved in blood vessel formation.
Should transgene expression be achieved, angiogenesis in embryos and
various adult tissues will be examined and endothelial cells could be isolated
to study cellular process such as proliferation, migration, and survival.
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